[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 126
1. Nozoe T, Oyama T, Mori E, Uramoto H, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K: Clinicopathologic significance of an immunohistochemical expression of p27 in scirrhous carcinoma of the breast. Breast Cancer; 2007;14(3):277-80
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic significance of an immunohistochemical expression of p27 in scirrhous carcinoma of the breast.
  • BACKGROUND: Scirrhous carcinoma has been known to have more aggressive biological behavior than other histologic subtypes of invasive ductal carcinoma of the breast.
  • The significance of expression of p27kip1, which is thought to be a tumor suppressor gene, in breast carcinoma remains controversial.
  • The aim of the current study was to clarify clinicopathologic significance of scirrhous carcinoma of the breast with special reference to p27 expression.
  • METHODS: Clinicopathologic features including immunohistochemical expression of p27 were compared between scirrhous carcinoma (n=42) and non-scirrhous invasive ductal carcinoma (papillotubular and solid-tubular carcinoma, n=63) of the breast.
  • RESULTS: The proportion of pathologic lymph node metastasis among scirrhous carcinomas was significantly higher than that among carcinomas of other histologic types (papillotubular or solid-tubular carcinomas, p=0.029).
  • The proportion of strong expression of p27 among scirrhous carcinomas was significantly lower than that among tumors of other histologic types (p<0.0001).
  • CONCLUSIONS: Biological behavior of scirrhous carcinoma was found to be aggressive.
  • The aggressiveness and poor cellular differentiation of scirrhous carcinoma of the breast might be related to low p27 expression.
  • [MeSH-major] Adenocarcinoma, Scirrhous / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Case-Control Studies. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690504.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


2. Hirai K, Kikuchi S, Kurita A, Ohashi S, Adachi E, Matsuoka Y, Nagata K, Watanabe M: Immunohistochemical distribution of heat shock protein 47 (HSP47) in scirrhous carcinoma of the stomach. Anticancer Res; 2006 Jan-Feb;26(1A):71-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical distribution of heat shock protein 47 (HSP47) in scirrhous carcinoma of the stomach.
  • BACKGROUND: The aim of the present study was to examine the immunohistochemical distribution of the 47-kDa heat shock protein (HSP47) to enhance the understanding of the mechanisms involved in stromal fibrosis, which accompanies cancer infiltration in scirrhous carcinoma of the stomach.
  • Tumor tissues were obtained from ten patients with early gastric cancer (5 scirrhous carcinoma; 5 non-scirrhous carcinoma) and three patients with advanced scirrhous gastric cancer.
  • Moreover, the number of fibroblasts in scirrhous gastric cancer was significantly greater than that in non-scirrhous gastric cancer (p = 0.0004).
  • CONCLUSION: These findings indicate that fibroblasts predominantly produce stromal collagen and may play an important role in the development of stromal change in scirrhous gastric cancer.
  • Further studies are required to elucidate the significance of HSP47 in the development of new clinical approaches for treating scirrhous gastric cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous / metabolism. HSP47 Heat-Shock Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Cell Line, Tumor. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475681.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / HSP47 Heat-Shock Proteins; 0 / SERPINH1 protein, human
  •  go-up   go-down


3. Shimizu T, Yamada Y, Yasui H, Shirao K, Fukuoka M: Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. Anticancer Res; 2005 Jul-Aug;25(4):2997-3001
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
  • A new oral DPD inhibitory fluoropyrimidine (DIF), S-1, is reportedly effective against gastric scirrhous carcinoma.
  • PATIENTS AND METHODS: In this study, the relationship between immunoreactivity to DPD in biopsy specimens and the effects of chemotherapy were investigated in 61 patients treated with first-line fluoropyrimidine-based chemotherapy (S-1:DIF, 5-FU:non-DIF) for gastric scirrhous carcinoma.
  • CONCLUSION: This study indicates that S-1 may be effective even in gastric scirrhous carcinoma with a high level of DPD activity.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / enzymology. Dihydrouracil Dehydrogenase (NADP) / metabolism. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / enzymology. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080558.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies; 0 / Drug Combinations; 0 / Pyridines; 0 / Recombinant Proteins; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Ohmura T, Umekita N, Ohkubo T, Tanaka S, Maeshiro T, Matsuo S, Miyamoto S, Inoue S, Kitamura M: [Local recurrence of pancreatic cancer successfully treated with gemcitabine]. Gan To Kagaku Ryoho; 2005 Feb;32(2):239-41
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was Stage IVb poorly-differentiated tubular adenocarcinoma, scirrhous type, pT4, PL (+), P0, H0, pN2.
  • Systemic chemotherapy was performed with a regimen of gemcitabine 1,000 mg/m2/week for 2 weeks, followed by a week rest.
  • Two years after the diagnosis of recurrence, he returned to work, and his chemotherapy is being continued as an outpatient.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pancreatic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751641.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


5. Hirasawa H, Tsushima Y, Hirasawa S, Takei H, Taketomi-Takahasi A, Takano A, Amanuma M, Endo K: Perfusion CT of breast carcinoma: arterial perfusion of nonscirrhous carcinoma was higher than that of scirrhous carcinoma. Acad Radiol; 2007 May;14(5):547-52
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion CT of breast carcinoma: arterial perfusion of nonscirrhous carcinoma was higher than that of scirrhous carcinoma.
  • Differences in perfusion between scirrhous and nonscirrhous carcinoma were also assessed.
  • The mean perfusion of nonscirrhous carcinoma (45.8 ml/min/100 ml; n = 11) was higher than that of scirrhous carcinoma (22.7 ml/min/100 ml; n = 11; P < .001).
  • CONCLUSION: Determination of the perfusion of breast carcinoma is feasible by dynamic CT and can be performed during a routine CT study without much supplementary burden on the patient.
  • There are differences in blood flow between scirrhous and nonscirrhous breast carcinoma, and further research is needed to determine the impact of this finding.
  • [MeSH-major] Adenocarcinoma, Scirrhous / radiography. Breast Neoplasms / radiography. Neovascularization, Pathologic / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434068.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; JR13W81H44 / Iopamidol
  •  go-up   go-down


6. Ohta T, Tsujimoto F, Nakajima Y, Fukuda M, Takag M: Ultrasonographic findings of invasive lobular carcinoma differentiation of invasive lobular carcinoma from invasive ductal carcinoma by ultrasonography. Breast Cancer; 2005;12(4):304-11
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic findings of invasive lobular carcinoma differentiation of invasive lobular carcinoma from invasive ductal carcinoma by ultrasonography.
  • BACKGROUND: Although controversy exists, invasive lobular carcinoma (ILC) differs in its high frequency of microscopically positive margins after conservative therapy compared to invasive ductal carcinoma (IDC).
  • We tried to confirm whether it is possible to distinguish ILC from other invasive carcinomas by ultrasonography (US).
  • METHODS: A total of 81 histologically confirmed cases of IDC, including 26 cases of papillotubular carcinoma, 28 cases of solid-tubular carcinoma and 27 cases of scirrhous carcinoma, as well as 24 cases of ILC were selected and retrospectively studied with regard to the features of mass lesions on US examination.
  • RESULTS: The sensitivities of US for papillotubular carcinoma, solid-tubular carcinoma, scirrhous carcinoma and ILC were 88.5%, 100%, 92.6% and 91.7% respectively.
  • One group had a low frequency of malignant findings and consisted of papillotubular and solid-tubular carcinomas, and the other group had a high frequency of malignant findings and consisted of scirrhous carcinomas and ILC.
  • However, there were no statistical differences between papillotubular carcinoma and solid-tubular carcinoma or between scirrhous carcinoma and ILC with regard to the US findings.
  • CONCLUSIONS: Scirrhous carcinoma, the most common type of IDC, and ILC are difficult to distinguish by US.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Lobular / ultrasonography. Neoplasm Invasiveness / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies. Sensitivity and Specificity


7. Tanaka M, Kamata R, Takigahira M, Yanagihara K, Sakai R: Phosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinoma. Am J Pathol; 2007 Jul;171(1):68-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinoma.
  • We investigated the involvement of ephrin-B1 in regulating the invasiveness of scirrhous gastric cancer, which is a diffusely infiltrative carcinoma with high invasion potential.
  • Reduction of ephrin-B1 expression by short inter-fering RNA or overexpression of phosphorylation-defective mutant suppressed migration and invasion of scirrhous gastric cancer cells in vitro without affecting tumor cell proliferation and apoptosis.
  • [MeSH-major] Adenocarcinoma, Scirrhous / metabolism. Ephrin-B1 / metabolism. Neoplasm Invasiveness. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1996 Oct 24;383(6602):722-5 [8878483.001]
  • [Cites] Cancer Res. 1986 May;46(5):2416-22 [3697985.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33 [15561600.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):323-32 [15958054.001]
  • [Cites] Nature. 2005 Jun 23;435(7045):1126-30 [15973414.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1197-206 [16211213.001]
  • [Cites] EMBO J. 2005 Nov 2;24(21):3700-11 [16211011.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):42375-82 [16236711.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):55-63 [16362052.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):936-43 [16424028.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):454-64 [16272170.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):217-23 [16773203.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1151-63 [16777604.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):883-9 [16784989.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7532-9 [16885351.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37 [16875667.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8492-500 [16951161.001]
  • [Cites] BMC Cancer. 2006;6:294 [17181871.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):174-9 [11557983.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jul;128(7):343-8 [12136247.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):862-9 [12209731.001]
  • [Cites] Cell. 2002 Oct 18;111(2):251-63 [12408869.001]
  • [Cites] EMBO J. 2003 Feb 17;22(4):847-58 [12574121.001]
  • [Cites] J Cell Sci. 2003 Jul 15;116(Pt 14):2823-32 [12808016.001]
  • [Cites] J Hepatol. 2003 Dec;39(6):991-6 [14642617.001]
  • [Cites] Biochem J. 2004 Jan 15;377(Pt 2):499-507 [14535844.001]
  • [Cites] EMBO J. 2004 Mar 10;23(5):1075-88 [14988728.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):575-82 [15245593.001]
  • [Cites] IUBMB Life. 2004 May;56(5):257-65 [15370889.001]
  • [Cites] Dev Cell. 2004 Oct;7(4):465-80 [15469835.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3726-33 [9920925.001]
  • (PMID = 17591954.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ephrin-B1
  • [Other-IDs] NLM/ PMC1941588
  •  go-up   go-down


8. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y, Yanagihara K, Sakai R: CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol; 2008 Jun;172(6):1729-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma.
  • In this study, we examined whether CDCP1 is involved in the regulation of tumor progression of scirrhous gastric cancer, which is a diffusely infiltrative carcinoma with high invasion potential.
  • Expression and phosphorylation levels of CDCP1 correlated with the invasive potential of scirrhous gastric cancers.
  • Reduction of CDCP1 expression by siRNA suppressed migration, invasion, and anchorage independence without affecting the proliferation of highly invasive scirrhous gastric cancer cells.
  • Expression and phosphorylation of CDCP1 were also detected in cancer cells of surgically resected tissues of human scirrhous gastric cancer by immunohistochemical analysis.
  • [MeSH-major] Adenocarcinoma, Scirrhous / metabolism. Antigens, CD / physiology. Cell Adhesion Molecules / physiology. Neoplasm Proteins / physiology. Peritoneal Neoplasms / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement. Humans. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Transplantation. Phosphorylation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2003 May;996:222-6 [12799299.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):149-57 [12673672.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14772-83 [14739293.001]
  • [Cites] Stem Cells. 2004;22(3):334-43 [15153610.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Aug;15(4):197-204 [15207811.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):575-82 [15245593.001]
  • [Cites] Cell. 1992 Apr 3;69(1):11-25 [1555235.001]
  • [Cites] Jpn J Cancer Res. 1992 Dec;83(12):1317-26 [1282908.001]
  • [Cites] J Mol Biol. 1993 May 20;231(2):539-45 [8510165.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):43-54 [8521616.001]
  • [Cites] J Cell Biol. 1996 Feb;132(4):727-40 [8647901.001]
  • [Cites] Nat Struct Biol. 1997 Oct;4(10):783-8 [9334740.001]
  • [Cites] Cell. 2005 Apr 22;121(2):271-80 [15851033.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):323-32 [15958054.001]
  • [Cites] Oncogene. 2005 Aug 11;24(34):5333-43 [16007225.001]
  • [Cites] Biol Cell. 2006 Sep;98(9):547-55 [16907663.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1530-41 [17101326.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):68-78 [17591954.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(21):7649-60 [17785447.001]
  • [Cites] Matrix Biol. 2008 Apr;27(3):201-10 [18042364.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):497-506 [10702200.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4402-8 [11466621.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):18069-76 [11886873.001]
  • [Cites] Oncogene. 2003 Mar 27;22(12):1783-94 [12660814.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12734-43 [14718544.001]
  • (PMID = 18467693.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CDCP1 protein, human; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2408431
  •  go-up   go-down


9. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K: A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology; 2006 Nov;131(5):1530-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
  • BACKGROUND & AIMS: Scirrhous gastric carcinoma carries the highest mortality of all gastric cancers.
  • The aim of the current study is to clarify the possibility of molecular target therapy with Ki23057 for treating scirrhous gastric cancer.
  • OCUM-2MD3 and OCUM-8 were derived from scirrhous carcinomas.
  • MKN-7, MKN-45, and MKN-74 cells were derived from nonscirrhous carcinomas.
  • Ki23057 significantly inhibited the proliferation of scirrhous cancer cells but not nonscirrhous gastric carcinoma cells.
  • Ki23057 decreased phosphorylation of K-samII/FGF-R2, extracellular signal-regulated kinase, and Akt and increased apoptosis in scirrhous cancer lines.
  • The oral Ki23057 administration significantly (P < .001) prolonged survival of mice with peritoneal dissemination following injection of OCUM-2MD3 scirrhous cancer cells.
  • CONCLUSIONS: A novel K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, appears therapeutically promising in scirrhous gastric carcinoma with K-samII amplification.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Protein Kinase Inhibitors / pharmacology. Quinolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Humans. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Peritoneal Neoplasms / pathology. Phosphorylation. Receptor, ErbB-2. Signal Transduction. Transplantation, Heterologous


10. Fujii T, Zen Y, Nakanuma Y: Minute scirrhous hepatocellular carcinomas undergoing different carcinogenetic processes. Pathol Int; 2007 Jul;57(7):443-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minute scirrhous hepatocellular carcinomas undergoing different carcinogenetic processes.
  • Scirrhous hepatocellular carcinoma (scirrhous HCC) is a rare histological subtype of HCC characterized by marked fibrosis along the sinusoid spaces.
  • Carcinogenetic processes and pathological features at earlier stages of scirrhous HCC remain unclarified.
  • In the present report two cases of minute scirrhous HCC suggesting different carcinogenesis, are described.
  • Histologically, the inner part of the tumor was well-differentiated HCC with prominent collagen fiber deposition along the sinusoids (scirrhous HCC), whereas the outer part was a high-grade dysplastic nodule.
  • At autopsy a hepatic tumor (1.2 cm in diameter) was incidentally found in the cirrhotic liver, and was histologically scirrhous HCC without dysplastic nodule elements.
  • Carcinoma cells proliferated along the cirrhotic fibrous septa and replaced regenerative nodules.
  • These two cases suggested that scirrhous HCC could occur in dysplastic nodules (the former case) and also develop de novo in cirrhotic liver (the latter case).
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587244.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Tabei I, Nishiyama S, Yamashita S, Hashimoto H, Tachibana T, Uchida K, Ishikawa H: Establishment and characterization of HER2-positive cell line derived from pleural effusion of human breast scirrhous carcinoma. Hum Cell; 2008 Nov;21(4):105-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of HER2-positive cell line derived from pleural effusion of human breast scirrhous carcinoma.
  • We have established a cell line derived from a pleural effusion of breast scirrhous carcinoma.
  • Enzyme and electrochemiluminescence immunoassays of tumor markers in the conditioned medium by the cell line revealed they secrete CA15-3, NCC-ST-439 and HER2 protein.
  • We believe the cell line will contribute to the therapeutic study of malignant breast cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous. Biomarkers, Tumor / analysis. Breast Neoplasms. Pleural Effusion, Malignant. Receptor, ErbB-2
  • [MeSH-minor] Animals. Antigens, Tumor-Associated, Carbohydrate / analysis. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Karyotyping. Mice. Middle Aged. Mucin-1 / analysis. Neoplasm Transplantation. Receptors, Estrogen. Receptors, Progesterone

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - SSILY (CVCL_M362) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067762.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / ST 439 antigen, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


12. Ohi S, Kyoda S, Tabei I, Ninomiya K, Sugiyama K, Hashimoto H, Tachibana T, Ishikawa H: Establishment and characterization of a cell line (NABCA) derived from metastatic lymph nodes of breast scirrhous carcinoma. Hum Cell; 2006 Nov;19(4):126-32
Cellosaurus - a cell line knowledge resource. culture/stock collections - NABCA (CVCL_M368) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cell line (NABCA) derived from metastatic lymph nodes of breast scirrhous carcinoma.
  • We successfully established a breast scirrhous carcinoma cell line (designated as NABCA) derived from metastatic tumors of the lymph node.
  • This cell line is useful for studying the mechanism of lymphatic metastasis and susceptibility of anticancer drugs in human breast scirrhous cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Breast Neoplasms / pathology. Cell Culture Techniques / methods
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Division. Cell Line, Tumor. Drug Resistance, Neoplasm. Female. Humans. Karyotyping. Lymphatic Metastasis. Male. Mice. Mice, Inbred BALB C. Microscopy, Electron. Middle Aged. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17257375.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Matsuura S, Aishima S, Taguchi K, Asayama Y, Terashi T, Honda H, Tsuneyoshi M: 'Scirrhous' type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology; 2005 Oct;47(4):382-90
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Scirrhous' type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1.
  • AIMS: 'Scirrhous' hepatocellular carcinoma (scirrhous HCC) is extremely rare and its characteristics remain unclear.
  • We investigated the clinicopathological and immunohistochemical features of scirrhous HCC, compared with those of ordinary hepatocellular carcinoma (ordinary HCC).
  • METHODS AND RESULTS: We compared the clinicopathological and immunohistochemical features of 20 resected cases of scirrhous HCC with those of 69 resected cases of ordinary HCC.
  • Scirrhous HCC was characterized by its gross and histological findings, such as a higher proportion of contiguous multinodular type tumours, the absence of a complete fibrous capsule around the tumour, the absence of tumour necrosis and highly preserved portal tracts in the tumour.
  • The immunohistochemical results revealed a significantly higher expression of cytokeratin 7 and a significantly lower expression of hepatocyte paraffin 1 in scirrhous HCC than in ordinary HCC (P<0.0001, respectively).
  • There were no significant differences in proliferative activity and survival curves between the patients with scirrhous HCC and those with ordinary HCC.
  • CONCLUSION: Scirrhous HCC has several particular gross, histological and immunohistochemical features.
  • In particular, we would like to emphasize the greater immunohistochemical expression of cytokeratin 7 and lower expression of hepatocyte paraffin 1 in scirrhous HCC than in ordinary HCC.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Carcinoma, Hepatocellular / pathology. Hepatocytes / metabolism. Keratins / metabolism. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178893.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


14. Tozaki M, Fukuda K, Suzuki M: Dynamic high-spatial-resolution MR imaging of invasive ductal carcinoma: influence of histological scirrhous component on MR descriptors. Magn Reson Med Sci; 2006 Oct;5(3):137-46
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic high-spatial-resolution MR imaging of invasive ductal carcinoma: influence of histological scirrhous component on MR descriptors.
  • PURPOSE: The purpose of this study was to assess the relationship between the amount of scirrhous component in invasive ductal carcinoma and its MR characteristics.
  • MATERIALS AND METHODS: We retrospectively reviewed 71 consecutive patients with invasive ductal carcinoma smaller than 25 mm (average, 16.6 mm) in diameter.
  • The scirrhous component was defined as invasive foci in small clusters of cancer cells showing desmoplasia.
  • Invasive ductal carcinoma was subclassified into 3 groups in accordance with the amount of the scirrhous component (scirrhous component degree; SCD): SCD I (scirrhous component less than 20%), SCD II (intermediate), and SCD III (more than 80%).
  • The presence of enhancing internal septations was significantly different between SCD I/II and SCD III carcinomas (P=0.05).
  • Central enhancement was only observed in SCD I carcinoma (4%; 3/71).
  • CONCLUSION: The histological predominance of the scirrhous component in invasive ductal carcinoma may be one explanation for the differences in morphologic and kinetic patterns on MR imaging.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Carcinoma, Ductal, Breast / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Invasiveness / diagnosis. Retrospective Studies

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139139.001).
  • [ISSN] 1347-3182
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Ikeguchi M, Kuroda H, Matsunaga T, Fukuda K, Saito H, Tatebe S: [Intra-peritoneal chemotherapy for scirrhous gastric cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2058-60
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-peritoneal chemotherapy for scirrhous gastric cancer].
  • Preoperative intra-peritoneal chemotherapy (IPC) for scirrhous gastric cancer (SGC) has been performed and followed after laparoscopic diagnosis of peritoneal metastasis (P) or washing cytology (CY) in our hospital.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037322.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, Nishio K, Ochiya T, Ino Y, Hirohashi S: Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci; 2005 Jun;96(6):323-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer.
  • The number of published studies on peritoneal dissemination of scirrhous gastric carcinoma is very small as a result of the unavailability of highly reproducible animal models.
  • Orthotopic implantation of HSC-44PE and HSC-58 (scirrhous gastric carcinoma-derived cell lines) cells into nude mice led to dissemination of the tumor cells to the greater omentum, mesenterium, peritoneum and so on, and caused ascites in a small number of animals.
  • This was to isolate highly metastatic cell lines with a strong capability of inducing the formation of ascites (44As3 from HSC-44PE; 58As1 and 58As9 from HSC-58).
  • The metastatic cell lines and the in vivo model established in the present study are expected to serve as a model of cancerous peritonitis developing from primary lesions, and as a useful means of clarifying the pathophysiology of peritoneal dissemination of scirrhous gastric carcinoma and the development of drugs for its treatment.
  • [MeSH-major] Adenocarcinoma, Scirrhous / secondary. Adenocarcinoma, Scirrhous / veterinary. Disease Models, Animal. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / veterinary. Stomach Neoplasms / pathology. Stomach Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958054.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Kunisaki C, Shimada H, Nomura M, Matsuda G, Otsuka Y, Ono H, Akiyama H: Therapeutic strategy for scirrhous type gastric cancer. Hepatogastroenterology; 2005 Jan-Feb;52(61):314-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic strategy for scirrhous type gastric cancer.
  • BACKGROUND/AIMS: As no appropriate therapeutic strategy has yet been established in scirrhous type gastric cancer, we retrospectively analyzed the therapeutic outcomes in patients with this type of cancer.
  • METHODOLOGY: A total of 183 patients with scirrhous type gastric cancer were enrolled in the study.
  • CONCLUSIONS: In scirrhous type gastric cancer, gastrectomy including extended lymph node dissection is justified only in patients with limited lymph node metastasis, and palliative gastrectomy should be not performed because it has no efficacy on survival.
  • [MeSH-major] Adenocarcinoma, Scirrhous / therapy. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783058.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Gollub MJ, Schwartz MB, Shia J: Scirrhous metastases to the gastrointestinal tract at CT: the malignant target sign. AJR Am J Roentgenol; 2009 Apr;192(4):936-40
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scirrhous metastases to the gastrointestinal tract at CT: the malignant target sign.
  • OBJECTIVE: Our objective was to study the presence of a characteristic appearance of metastatic disease to the gastrointestinal tract on contrast-enhanced CT in patients with known malignancies and to investigate its clinical implications.
  • CONCLUSION: Twenty-five patients with scirrhous metastases had a malignant CT target sign.
  • [MeSH-major] Adenocarcinoma, Scirrhous / radiography. Adenocarcinoma, Scirrhous / secondary. Gastrointestinal Neoplasms / radiography. Gastrointestinal Neoplasms / secondary. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):463-6 [10658725.001]
  • [Cites] AJR Am J Roentgenol. 1979 May;132(5):711-5 [219672.001]
  • [Cites] AJR Am J Roentgenol. 1991 Jan;156(1):23-32 [1898566.001]
  • [Cites] AJR Am J Roentgenol. 1995 Oct;165(4):839-45 [7676978.001]
  • [Cites] Gastroenterology. 1965 Apr;48:419-24 [14275076.001]
  • (PMID = 19304697.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ NIHMS470464; NLM/ PMC3712505
  •  go-up   go-down


19. Kim SH, Lim HK, Lee WJ, Choi D, Park CK: Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection. Eur J Radiol; 2009 Jan;69(1):123-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection.
  • OBJECTIVE: To compare the CT and pathologic features and the long-term results of scirrhous hepatocellular carcinoma (HCC) after a curative resection with those of usual HCC.
  • METHODS: Twenty-one patients with a scirrhous HCC and 296 patients with a usual HCC underwent contrast-enhanced triple-phase helical CT examinations before and after the curative resection.
  • The CT and pathological features of scirrhous HCC, along with the cumulative survival and recurrence rates after the curative resection using a Kaplan-Meier method were compared with those of a usual HCC.
  • RESULTS: The common CT features of scirrhous HCC were an ill-defined tumor margin (76%), peripheral rim-like enhancement on arterial and portal phases (62%), presence of area of prolonged and delayed enhancement on equilibrium phase (95%), and hepatic surface retraction (59%) and the uncommon CT features were presence of washout area (19%) and tumor capsule enhancement (5%), which were significantly different from those of usual HCC (p<0.05).
  • CONCLUSION: Scirrhous HCC showed distinct CT and pathologic features from those of usual HCC.
  • After the curative resection, the long-term results of scirrhous and usual HCCs were not significantly different.
  • [MeSH-major] Adenocarcinoma, Scirrhous / radiography. Adenocarcinoma, Scirrhous / surgery. Carcinoma, Hepatocellular / radiography. Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / radiography. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976942.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


20. Ikeguchi M, Miyake T, Matsunaga T, Yamamoto M, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S, Tsujitani S: Recent results of therapy for scirrhous gastric cancer. Surg Today; 2009;39(4):290-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent results of therapy for scirrhous gastric cancer.
  • The prognosis of patients with scirrhous gastric cancer (SGC) is extremely poor.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319634.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


21. Ikeguchi M, Matsumoto S, Yoshioka S, Murakami D, Kanaji S, Ohro S, Yamaguchi K, Saito H, Tatebe S, Kondo A, Tsujitani S, Kaibara N: Laparoscopic-assisted intraperitoneal chemotherapy for patients with scirrhous gastric cancer. Chemotherapy; 2005 Mar;51(1):15-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted intraperitoneal chemotherapy for patients with scirrhous gastric cancer.
  • BACKGROUND: The prognosis for patients with scirrhous gastric cancer (SGC) is extremely poor.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Cisplatin / therapeutic use. Injections, Intraperitoneal. Laparoscopy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Female. Gene Expression. Genes, myc / genetics. Humans. Inhibitor of Apoptosis Proteins. Interleukins / genetics. Male. Microtubule-Associated Proteins / genetics. Middle Aged. Neoplasm Proteins. Peritoneal Cavity. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transforming Growth Factor beta / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15722628.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Interleukins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transforming Growth Factor beta; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Wray JD, Blunden AS: Progressive dysphagia in a dog caused by a scirrhous, poorly differentiated perioesophageal carcinoma. J Small Anim Pract; 2006 Jan;47(1):27-30
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive dysphagia in a dog caused by a scirrhous, poorly differentiated perioesophageal carcinoma.
  • The case of a seven-year-old Border collie that presented with a history of progressive pharyngeal dysphagia is described.
  • Fluoroscopic investigation was initially suggestive of functional pharyngeal disease, but magnetic resonance imaging and surgical exploration demonstrated the presence of a diffuse, scirrhous, poorly differentiated carcinoma with extensive oesophageal involvement.
  • [MeSH-major] Adenocarcinoma, Scirrhous / veterinary. Deglutition Disorders / veterinary. Dog Diseases / diagnosis. Dog Diseases / etiology. Esophageal Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417607.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


23. Suzuki M, Ishikawa H, Tanaka A, Mataga I: Anticancer drug sensitivity testing using an oxygen electrode apparatus. Hum Cell; 2010 Aug;23(3):103-12
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we developed an oxygen electrode apparatus that uses cellular metabolism as an indicator of anticancer drug sensitivity and investigated its usefulness in 29 breast cancer patients with the following histopathological classifications: papillotubular carcinoma (n= 15); solid tubular carcinoma (n= 6); and scirrhous carcinoma (n= 8).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / pathology. Antineoplastic Agents / pharmacology. Breast Neoplasms / pathology. Carcinoma, Papillary / pathology. Drug Screening Assays, Antitumor / instrumentation. Electrodes. Oxygen / analysis
  • [MeSH-minor] Animals. Female. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Reproducibility of Results. Sensitivity and Specificity. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Human Cell © 2010 Japan Human Cell Society.
  • (PMID = 20973835.001).
  • [ISSN] 1749-0774
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; S88TT14065 / Oxygen
  •  go-up   go-down


24. Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M: Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol; 2006 Sep;21(9):1470-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of scirrhous hepatocellular carcinoma.
  • BACKGROUND AND AIMS: Scirrhous hepatocellular carcinoma (SHCC) is characterized by diffuse fibrosis of the tumor, however, its clinicopathological features are not fully clarified.
  • METHODS: Among 546 consecutively resected HCC without preoperative anticancer therapies, 25 SHCC were selected for the study and compared with 521 cases without scirrhous as the control.
  • On diagnostic imagings, SHCC was frequently misdiagnosed as cholangiocarcinoma (CC), combined HCC-CC or metastatic carcinoma.
  • SHCC was characterized by stellate fibrosis (84%), no encapsulation (100%), no necrosis and hemorrhage (100%), intratumoral portal tracts (80%), remarkable lymphocyte infiltration (84%), clear cell change (84%), and hyaline bodies (52%).
  • Regarding the developmental mechanism of scirrhous change, a close correlation with unique tumor location and activation of stellate cells was suggested.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / physiopathology. Liver Neoplasms / pathology. Liver Neoplasms / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Liver Function Tests. Male. Middle Aged. Survival Rate. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911695.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


25. Tanaka M, Sasaki K, Kamata R, Hoshino Y, Yanagihara K, Sakai R: A novel RNA-binding protein, Ossa/C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis. Mol Cell Biol; 2009 Jan;29(2):402-13
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an attempt to identify the SFK-binding proteins selectively phosphorylated in gastric scirrhous carcinoma, we identified an uncharacterized protein, C9orf10.
  • [MeSH-minor] Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Animals. Catalytic Domain / physiology. Cell Line, Tumor. Disease Models, Animal. Humans. Insulin-Like Growth Factor II / metabolism. Insulin-Like Growth Factor II / secretion. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Phosphatidylinositol 3-Kinases / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. src Homology Domains / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Biochem. 2000 Jun;33(4):279-84 [10936586.001]
  • [Cites] J Histochem Cytochem. 2008 Aug;56(8):723-31 [18413649.001]
  • [Cites] Nature. 2000 Nov 23;408(6811):492-5 [11100733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1543-8 [11171987.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):489-95 [11304462.001]
  • [Cites] Breast Cancer Res. 2001;3(5):323-7 [11597322.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):366-71 [11694531.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2002 Sep-Oct;15(5):342-7 [12239429.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):951-6 [12459733.001]
  • [Cites] Gene. 2003 Oct 30;318:149-61 [14585507.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1940-9 [14612907.001]
  • [Cites] Biochim Biophys Acta. 2003 Dec 5;1653(2):73-86 [14643926.001]
  • [Cites] J Neurochem. 2004 May;89(3):613-26 [15086518.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):470-80 [15170449.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):575-82 [15245593.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):7928-46 [15489911.001]
  • [Cites] Cancer Cells. 1991 Jan;3(1):1-7 [2025490.001]
  • [Cites] Cell. 1992 Dec 24;71(7):1081-91 [1473146.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):16-22 [7820952.001]
  • [Cites] Biochem J. 1995 Apr 1;307 ( Pt 1):225-31 [7717979.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4293-6 [7671238.001]
  • [Cites] Nature. 1997 Feb 13;385(6617):602-9 [9024658.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20389-94 [9252345.001]
  • [Cites] Int J Oncol. 1998 Sep;13(3):519-23 [9683787.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1262-70 [9891060.001]
  • [Cites] Mol Carcinog. 1999 Jan;24(1):15-24 [10029406.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48716-24 [15355996.001]
  • [Cites] Cell Mol Life Sci. 2005 Jan;62(1):36-43 [15619005.001]
  • [Cites] Can J Physiol Pharmacol. 2006 Jul;84(7):777-86 [16998541.001]
  • [Cites] Cell Death Differ. 2007 Feb;14(2):368-77 [16841086.001]
  • [Cites] Cell Signal. 2007 May;19(5):1081-92 [17275257.001]
  • [Cites] J Pharm Sci. 2007 Sep;96(9):2181-96 [17593552.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(21):7649-60 [17785447.001]
  • [Cites] Antioxid Redox Signal. 2008 Feb;10(2):207-47 [17999631.001]
  • [Cites] J Biol Chem. 2008 Jan 18;283(3):1480-91 [18024423.001]
  • [Cites] J Cell Biochem. 2008 May 15;104(2):657-67 [18172854.001]
  • [Cites] Am J Pathol. 2008 Jun;172(6):1729-39 [18467693.001]
  • [Cites] Growth Horm IGF Res. 2008 Aug;18(4):298-306 [18269934.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2175-83 [11031201.001]
  • (PMID = 19015244.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FAM120A protein, human; 0 / RNA-Binding Proteins; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.2 / src-Family Kinases
  • [Other-IDs] NLM/ PMC2612507
  •  go-up   go-down


26. Sugiki T, Yamamoto M, Taka K, Nakano M: Specific characteristics of scirrhous hepatocellular carcinoma. Hepatogastroenterology; 2009 Jul-Aug;56(93):1086-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific characteristics of scirrhous hepatocellular carcinoma.
  • BACKGROUND/AIMS: Scirrhous hepatocellular carcinoma has been defined within general hepatocellular carcinoma.
  • To define scirrhous hepatocellular carcinoma, the present study identified the specific characteristics as compared with general hepatocellular carcinoma.
  • METHODOLOGY: The scirrhous hepatocellular carcinoma was defined when almost all areas of the tumor were occupied with scirrhous structures.
  • It was identified 14 patients with scirrhous hepatocellular carcinoma and 300 patients with general hepatocellular carcinoma (control), all underwent hepatectomy from 1988 to 1994.
  • RESULTS: All scirrhous hepatocellular carcinoma showed whitish, hard forms resembling intrahepatic cholangiocarcinoma.
  • The rates of average ICGR15, positive hepatitis C virus antibody, and microscopic invasion to the bile duct were 12%, 33%, and 20%, respectively, each significantly different than general hepatocellular carcinoma.
  • The cumulative 10-year survival rate of scirrhous hepatocellular carcinoma and general hepatocellular carcinoma were 70% and 31%, respectively.
  • With immunohistological staining, 43% of scirrhous hepatocellular carcinoma showed negative staining for Hepatocyte Paraffin 1.
  • CONCLUSIONS: The scirrhous hepatocellular carcinoma has specific characteristics such as lower rates of hepatitis C virus infection, better prognosis, and different histological findings; therefore, scirrhous hepatocellular carcinoma should be strictly classified under a new category.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Adenocarcinoma, Scirrhous / surgery. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760947.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


27. Namiki Y, Namiki T, Yoshida H, Date M, Yashiro M, Matsumoto K, Nakamura T, Yanagihara K, Tada N, Satoi J, Fujise K: Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. Int J Cancer; 2006 Mar 15;118(6):1545-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.
  • We evaluated the effect of a "tailor-made" chemo-gene therapy in scirrhous gastric cancer (SGC)-bearing nude mice.
  • Finally, mice were peritoneally coinoculated with NUGC-4 and scirrhous-associated gastric fibroblasts, NF22, on day 0.
  • NK4-expression suppressed the gefitinib-resistance induced by the interaction between fibroblasts and SGC, and eventually, this tailor-made combination synergistically decelerated the disease progression by inhibiting proliferative, angiogenic and antiapoptotic effects in tumor tissues.
  • [MeSH-major] Adenocarcinoma, Scirrhous / therapy. Genetic Therapy / methods. Hepatocyte Growth Factor / genetics. Quinazolines / pharmacology. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206271.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / HGF protein, human; 0 / Quinazolines; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


28. Ogawa M, Watanabe M, Eto K, Kosuge M, Yamagata T, Kobayashi T, Yamazaki K, Anazawa S, Yanaga K: Poorly differentiated adenocarcinoma of the colon and rectum: clinical characteristics. Hepatogastroenterology; 2008 May-Jun;55(84):907-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated adenocarcinoma of the colon and rectum: clinical characteristics.
  • BACKGROUND/AIMS: The aims of this study were to assess the prognosis and histopathological factors of poorly differentiated colorectal adenocarcinoma, and the clinical relevance of the proposed histopathological sub classifications.
  • METHODOLOGY: Fifty eight patients with poorly differentiated adenocarcinoma were enrolled in this study.
  • Next, they were sub classified into medullary, intermediate and scirrhous types according to the amount of fibrous stroma.
  • In the lymphangitic types, 5 cases were medullary type (15%), 17 cases were intermediate type (52%) and 11 cases were scirrhous type (33%) that included 2 cases of signet ring cell carcinoma.
  • In the non-lymphangitic types, medullary type was dominant (20 cases, 80%) while intermediate type and scirrhous type were 3 cases (12%) and 2 cases (8%), respectively.
  • CONCLUSIONS: In conclusion, a wide tumor infiltration and growth in lymphatic vessels appears to be an important prognostic factor for poorly differentiated adenocarcinoma compared to the metastasis patterns.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon / pathology. Colon / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Rectum / pathology. Rectum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705295.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


29. Tendo M, Yashiro M, Nakazawa K, Yamada N, Hirakawa K: Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells. Cancer Sci; 2005 Jul;96(7):451-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells.
  • We therefore investigated the effect of a COX-2 inhibitor, JTE-522, on the ability of orthotopic fibroblasts to stimulate invasion of scirrhous gastric carcinoma cells.
  • The human scirrhous gastric cancer cell lines OCUM-2D or OCUM-2M, and human gastric fibroblasts (NF-21) were cultured in the absence or presence of JTE-522 at various concentrations.
  • In conclusion, we found that gastric fibroblasts stimulated invasiveness in scirrhous gastric cancer cells, whereas a selective COX-2 inhibitor inhibited this paracrine effect by decreasing fibroblast PGE2 production, resulting in downregulation of HGF production.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents / pharmacology. Benzenesulfonates / pharmacology. Cyclooxygenase Inhibitors / pharmacology. Fibroblasts / drug effects. Oxazoles / pharmacology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053517.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Cyclooxygenase Inhibitors; 0 / Oxazoles; 0 / Prostaglandins E; 67256-21-7 / Hepatocyte Growth Factor; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M, Hirakawa K: Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci; 2009 Dec;100(12):2402-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer.
  • Two scirrhous gastric cancer cell lines and two non-scirrhous gastric cancer cell lines were used.
  • The apoptosis of cancer cells and the expression of apoptosis-related molecules were examined by flow cytometry, real-time PCR, and immunostaining. mTOR inhibitors with 5FU showed a synergistic antiproliferative effect in scirrhous gastric cancer, whereas the other signal inhibitors showed no synergistic effect with any anticancer drugs. mTOR inhibitor decreased the IC(50) of 5FU and increased the apoptosis rate in scirrhous gastric cancer cells, but not in non-scirrhous gastric cancer cells.
  • The pan-caspase inhibitor, zVAD-fmk, inhibits apoptosis induced in combination with 5FU and mTOR inhibitor. mTOR inhibitor decreased dihydropyrimidine dehydrogenase, thymidylatesynthase, and bcl-2 expression, and increased caspase-3 and p21 expression of scirrhous gastric cancer cells, but did not affect those of non-scirrhous gastric cancer cells.
  • These findings suggest that mTOR inhibitor interacts with 5FU in a synergistic manner in scirrhous gastric cancer cells by the activation of the apoptosis signal.
  • Therefore, mTOR inhibitor is a promising therapeutic agent in combination with 5FU in scirrhous gastric cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764996.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Intracellular Signaling Peptides and Proteins; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Kameyama S, Murayama R, Miyazato K, Kurashita K, Ishimine T, Nagamine Y, Kohakura F, Shinzato S, Tomimori K, Kugai Y, Uchima H: [A case of scirrhous gastric cancer responding to TS-1/CDDP neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2006 Apr;33(4):509-11
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of scirrhous gastric cancer responding to TS-1/CDDP neoadjuvant chemotherapy].
  • A 72-year-old female with scirrhous-type advanced gastric cancer was treated with TS-1/CDDP as neoadjuvant chemotherapy.
  • The histological diagnosis revealed complete disappearance of cancer cells in the stomach and a few regional lymph node metastases (3/67).
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612163.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A, Hirakawa K: Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice. Cancer Sci; 2010 Aug;101(8):1846-52
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
  • The aim of this study was to clarify the effect of a TGF-beta receptor I (TbetaR-I) phosphorylation inhibitor, Ki26894, in combination with anticancer drugs, on the lymph node (LN) metastasis of scirrhous gastric cancer.
  • The human scirrhous gastric cancer cell line OCUM-2MLN and the human gastric fibroblasts NF-33 were used.
  • Gastric cancer models established by orthotopic inoculation of OCUM-2MLN cells showed diffusely infiltrating gastric adenocarcinoma accompanied by LN metastases.
  • These findings suggested that the TbetaR-I kinase inhibitor with S1 is useful for the treatment of scirrhous gastric carcinoma with LN metastasis. (Cancer Sci 2010).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518790.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Ki26894; 0 / Receptors, Transforming Growth Factor beta; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta1; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / Activin Receptors, Type I
  •  go-up   go-down


33. Kawajiri H, Yashiro M, Shinto O, Nakamura K, Tendo M, Takemura S, Node M, Hamashima Y, Kajimoto T, Sawada T, Ohira M, Hirakawa K: A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res; 2008 May 1;14(9):2850-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
  • PURPOSE: Transforming growth factor beta receptor (TGFbeta-R) is reported to correlate with the malignant potential of scirrhous gastric carcinoma.
  • The aim of the current study is to clarify the possibility of molecular target therapy with a TGFbeta-R inhibitor, A-77, for the treatment of peritoneal dissemination of scirrhous gastric cancer.
  • EXPERIMENTAL DESIGN: Three scirrhous gastric cancer cell lines and two fibroblasts were used.
  • The histologic findings showed the degree of fibrosis to be less in the tumors treated by A-77.
  • CONCLUSION: The TGFbeta-R inhibitor, A-77, decreased the expression of integrins in cancer cells and the proliferation of fibroblasts, which resulted in the decreased adhesive and invasive abilities of scirrhous gastric cancer cells to peritoneum.
  • A-77 is thus considered to be useful for the inhibition of peritoneal dissemination of scirrhous gastric carcinoma.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents / therapeutic use. Neoplasm Metastasis / prevention & control. Peritoneal Neoplasms / secondary. Pyrazoles / therapeutic use. Quinolines / therapeutic use. Receptors, Transforming Growth Factor beta / antagonists & inhibitors. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Humans. Integrins / metabolism. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Phosphorylation. RNA, Small Interfering / metabolism. Smad2 Protein / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451253.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / A-77 compound; 0 / Antineoplastic Agents; 0 / Integrins; 0 / Pyrazoles; 0 / Quinolines; 0 / RNA, Small Interfering; 0 / Receptors, Transforming Growth Factor beta; 0 / Smad2 Protein
  •  go-up   go-down


34. Kim SR, Imoto S, Nakajima T, Ando K, Mita K, Fukuda K, Nishikawa R, Koma Y, Matsuoka T, Kudo M, Hayashi Y: Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studies. World J Gastroenterol; 2009 May 14;15(18):2296-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studies.
  • We describe a 15-mm scirrhous hepatocellular carcinoma (HCC) in a 60-year-old man with B-type cirrhosis.
  • Histologically, the nodule was moderately-differentiated HCC characterized by typical cytological and structural atypia with dense fibrosis.
  • From the above findings, the nodule was diagnosed as scirrhous HCC.
  • Clinicians engaged in hepatology should exercise caution with suspected scirrhous HCC when imaging studies reveal atypical findings, as shown in our case on the basis of chronic liver disease.
  • [MeSH-major] Adenocarcinoma, Scirrhous. Carcinoma, Hepatocellular

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1980 Jul 15;46(2):372-9 [6248194.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Sep;21(9):1470-7 [16911695.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):784-94 [2456977.001]
  • [Cites] Liver. 1981 Mar;1(1):33-49 [6294435.001]
  • (PMID = 19437576.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2682251
  •  go-up   go-down


35. Kato Y, Yashiro M, Noda S, Tendo M, Kashiwagi S, Doi Y, Nishii T, Matsuoka J, Fuyuhiro Y, Shinto O, Sawada T, Ohira M, Hirakawa K: Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma. Br J Cancer; 2010 Mar 2;102(5):898-907
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma.
  • METHODS: We established a scirrhous gastric carcinoma cell line (OCUM-12) from ascites associated with scirrhous gastric carcinoma, and a hypoxia-resistant cancer cell line (OCUM-12/Hypo) was cloned from OCUM-12 cells by continuous exposure to 1% oxygen.
  • RESULTS: Histologic findings from orthotopic tumours derived from parent OCUM-12 cells and daughter OCUM-12/Hypo cells revealed poorly differentiated adenocarcinoma with extensive fibrosis that resembled human scirrhous gastric cancer.
  • CONCLUSION: OCUM-12 and OCUM-12/Hypo may be useful for the elucidation of disease progression associated with scirrhous gastric cancer in the setting of chronic hypoxia.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Anoxia. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - OCUM-12 (CVCL_8380) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - OCUM-12/Hypo (CVCL_8381) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8322-30 [11719466.001]
  • [Cites] Curr Opin Genet Dev. 2009 Aug;19(4):338-42 [19464162.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):237-50 [12741682.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1437-47 [14507651.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7634-7 [14633681.001]
  • [Cites] Lancet. 1971 Oct 30;2(7731):971-2 [4107917.001]
  • [Cites] Br J Radiol. 1979 Aug;52(620):650-6 [486895.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1245-8 [528271.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11 Suppl A:173-8 [6428739.001]
  • [Cites] Acta Pathol Jpn. 1986 Jan;36(1):65-83 [3962675.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Cancer Res. 1987 Jul 1;47(13):3496-503 [3581084.001]
  • [Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]
  • [Cites] J Cancer Res Clin Oncol. 1990;116(2):121-31 [2157713.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):354-61 [7678075.001]
  • [Cites] Gene. 1993 Nov 15;133(2):279-84 [8224915.001]
  • [Cites] Oncogene. 1994 Mar;9(3):963-9 [8108142.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1200-10 [7577468.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):43-54 [8521616.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • [Cites] Oncogene. 1998 Jun 4;16(22):2949-54 [9671416.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):266-76 [11181773.001]
  • [Cites] Jpn J Cancer Res. 2001 Jul;92(7):748-54 [11473725.001]
  • [Cites] Mol Pathol. 1998 Apr;51(2):55-61 [9713587.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):893-900 [15546507.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:10-7 [15591418.001]
  • [Cites] Cancer Sci. 2005 Apr;96(4):212-7 [15819718.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):334-40 [16495697.001]
  • [Cites] Curr Biol. 2006 Jun 20;16(12):1224-31 [16782014.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):965-71 [16935971.001]
  • [Cites] Placenta. 2008 Jan;29(1):51-7 [17959243.001]
  • [Cites] Am J Pathol. 2008 Feb;172(2):309-20 [18202198.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1003-11 [18281474.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4719-26 [18559518.001]
  • [Cites] Dis Colon Rectum. 2008 Sep;51(9):1387-94 [18546042.001]
  • [Cites] BMC Cancer. 2009;9:27 [19161638.001]
  • [Cites] Histopathology. 2009 Mar;54(4):442-51 [19309396.001]
  • [Cites] PLoS One. 2009;4(7):e6381 [19636430.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • (PMID = 20145613.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2833244
  •  go-up   go-down


36. Ninomiya K, Ohi S, Tabei I, Jin S, Tachibana T, Yamashita S, Yanaga K, Hashimoto H: Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type. Hum Cell; 2007 Aug;20(3):85-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type.
  • A graft in nude mouse after xenotransplantation was diagnosed as scirrhous carcinoma.
  • Radioimmunoassay indicated secretion of HER-2 protein, NCC-ST-439 and CA15-3.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Cell Line, Tumor. Pleural Effusion / pathology
  • [MeSH-minor] Adult. Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Female. Genes, erbB-2. Humans. Immunohistochemistry. Karyotyping. Mice. Mice, Nude. Microscopy, Electron. Neoplasm Recurrence, Local. Neoplasm Transplantation. Transplantation, Heterologous. Trastuzumab


37. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A, Hirakawa K: Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer; 2010 Mar 2;102(5):844-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
  • METHODS: Four gastric cancer cell lines, including two scirrhous-type cell lines and two non-scirrhous-type cell lines, were used.
  • RESULTS: TbetaR-I, TbetaR-II, and phospho-Smad2 expressions were found in scirrhous gastric cancer cells, but not in non-scirrhous gastric cancer cells.
  • Ki26894 decreased Smad2 phosphorylation induced by TGF-beta1 in scirrhous gastric cancer cells.
  • Transforming growth factor-beta1 upregulated the invasion, migration, and EMT ability of scirrhous gastric cancer cells.
  • Transforming growth factor-beta1 significantly upregulated the activity of RhoA and myosin phosphorylation, whereas TGF-beta1 decreased ZO-2 and E-cadherin expression in scirrhous gastric cancer cells.
  • Interestingly, Ki26894 inhibited these characteristics in scirrhous gastric cancer cells.
  • In contrast, non-scirrhous gastric cancer cells were not affected by TGF-beta1 or Ki26894 treatment.
  • CONCLUSION: A TbetaR-I kinase inhibitor decreases the invasiveness and EMT of scirrhous gastric cancer cells.
  • Ki26894 is therefore considered to be a promising therapeutic compound for the metastasis of scirrhous gastric carcinoma.
  • [MeSH-major] Activin Receptors, Type I / antagonists & inhibitors. Adenocarcinoma, Scirrhous / drug therapy. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Receptors, Transforming Growth Factor beta / antagonists & inhibitors. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Blotting, Western. Cell Movement / drug effects. Female. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Phosphorylation / drug effects. Signal Transduction / drug effects. Smad2 Protein / metabolism. Smad3 Protein / metabolism. Transforming Growth Factor beta / pharmacology. Wound Healing / drug effects

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1997 Dec 4;390(6659):465-71 [9393997.001]
  • [Cites] J Cell Biol. 1997 Nov 17;139(4):1047-59 [9362522.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):314-8 [15783058.001]
  • [Cites] Curr Biol. 2006 Jun 20;16(12):1224-31 [16782014.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):1083-97 [17215519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3460-5 [17307870.001]
  • [Cites] Cancer Sci. 2007 Jan;98(1):127-33 [17129361.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10123-8 [17974953.001]
  • [Cites] Am J Pathol. 2008 Feb;172(2):309-20 [18202198.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2850-60 [18451253.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):1070-6 [18310088.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Mol Biol Cell. 2008 Sep;19(9):3801-11 [18596233.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9107-11 [19010878.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):245-53 [19010789.001]
  • [Cites] Cancer Sci. 2009 Jan;100(1):181-8 [19037991.001]
  • [Cites] Surg Today. 2009;39(4):290-4 [19319634.001]
  • [Cites] J Natl Cancer Inst. 2009 Apr 15;101(8):592-604 [19351925.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2009 Jun;4(2):110-24 [19519534.001]
  • [Cites] Curr Opin Genet Dev. 2009 Aug;19(4):338-42 [19464162.001]
  • [Cites] Ups J Med Sci. 1999;104(3):217-29 [10680955.001]
  • [Cites] Eur J Surg Oncol. 2000 Jun;26(4):377-80 [10873359.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4489-93 [11205293.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Mech Dev. 2003 Nov;120(11):1351-83 [14623443.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8848-52 [14695201.001]
  • [Cites] Am J Surg. 2004 Sep;188(3):327-32 [15450843.001]
  • [Cites] Acta Pathol Jpn. 1986 Jan;36(1):65-83 [3962675.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Int J Cancer. 1989 Sep 15;44(3):394-8 [2777404.001]
  • [Cites] Cancer Res. 1993 Jan 1;53(1):183-90 [8416744.001]
  • [Cites] Br J Cancer. 1994 Apr;69(4):777-83 [8142266.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1668-75 [8608560.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1096-103 [8855981.001]
  • [Cites] Jpn J Cancer Res. 1997 Feb;88(2):152-9 [9119743.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):582-7 [9778627.001]
  • (PMID = 20145621.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki26894; 0 / Receptors, Transforming Growth Factor beta; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / Activin Receptors, Type I; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ PMC2833252
  •  go-up   go-down


38. Koufuji K, Aoyagi K, Yano S, Murakami N, Miyagi M, Imaizumi T, Shirouzu K: [Peritoneal dissemination of scirrhous type 4 gastric cancers]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1384-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal dissemination of scirrhous type 4 gastric cancers].
  • We examined 198 cases of primary scirrhous type 4 gastric cancer at our department from 1984 to 2003.
  • The essential cause of inoperability was peritoneal dissemination with malignant abdominal abscises.
  • One case with type 4 gastric cancer who had right hydronephrosis and malignant abdominal ascites underwent curative resection after successful treatment with TS-1.
  • [MeSH-major] Adenocarcinoma, Scirrhous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227734.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


39. Rodríguez-Marco NA, Domínguez-Polo AM, Cristóbal-Bescós JA, Sierra-Barreras J, Castillo-Laguarta J: [Proptosis as the first sign of recurrent scirrhous breast carcinoma]. Arch Soc Esp Oftalmol; 2005 Dec;80(12):737-40
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Proptosis as the first sign of recurrent scirrhous breast carcinoma].
  • [Transliterated title] Proptosis como primera manifestación de recidiva de cáncer escirro de mama.
  • OBJECTIVE: To inform clinicians of a metastatic orbital neoplasm that frequently masquerades as an orbital inflammatory syndrome.
  • CASE REPORT: The case of a 61-year-old woman, diagnosed and treated seven years ago for a scirrhous breast carcinoma is presented.
  • [MeSH-major] Adenocarcinoma, Scirrhous / secondary. Breast Neoplasms / pathology. Exophthalmos / diagnosis. Neoplasm Recurrence, Local / pathology. Orbital Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372219.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


40. Nakamura R, Saikawa Y, Wada N, Yoshida M, Kubota T, Kumai K, Kitajima M: Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience. Int J Clin Oncol; 2007 Aug;12(4):291-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience.
  • BACKGROUND: Scirrhous gastric cancer is biologically aggressive, and the prognosis is poor even with curative surgery.
  • RESULTS: Cumulative 5-year overall survival was 10.2% for all 83 patients, including 27 (32.5%) patients with stage II/III disease and 56 (67.4%) with stage IV disease.
  • The 5-year overall survival rate and median survival time for patients with stage II/III disease after curative surgery were 24.3% and 1150 days.
  • For patients with stage IV disease, 2-year and 5-year survival rates after initial surgery were 13.7% and 0% and median survival was 250 days.
  • In contrast, preoperative chemotherapy for advanced, unresectable disease produced 2-year and 3-year overall survival rates of 53.6% and 26.8% and medican survival was 910 days.
  • [MeSH-major] Adenocarcinoma, Scirrhous / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701009.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Matsui H, Nagashima A, Kawaoka T, Hiraki S, Fukuda S: [A case of giant breast cancer performed a radical excision after neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2487-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological examination of resected specimens revealed scirrhous carcinoma with invasion to pectoralis major and skin, but no cancer cell was seen on the excised margin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037464.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Tendo M, Yashiro M, Nakazawa K, Yamada N, Sawada T, Ohira M, Hirakawa K: A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett; 2006 Dec 8;244(2):247-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
  • An inhibitory-effect of a selective cyclooxygenase-2 (COX-2) inhibitor on peritoneal metastasis of scirrhous gastric carcinoma was investigated in vivo.
  • Peritoneal metastasis had developed after intraperitoneal inoculation of scirrhous gastric cancer cells, OCUM-2MD3, in nude mice.
  • These findings suggested that combining S-1 and COX-2 inhibitor administration obtain a synergistic inhibitory-effect on the peritoneal metastasis of scirrhous gastric carcinoma.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Benzenesulfonates / therapeutic use. Cyclooxygenase 2 Inhibitors / therapeutic use. Oxazoles / therapeutic use. Oxonic Acid / therapeutic use. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16448745.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; 0 / Antimetabolites, Antineoplastic; 0 / Benzenesulfonates; 0 / Cyclooxygenase 2 Inhibitors; 0 / Drug Combinations; 0 / Oxazoles; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


43. Satoh D, Ninomiya M, Umeoka T, Harano M, Sasaki H, Aoki H, Onoda T, Shiozaki Y, Ohno S, Higaki K, Takakura N: [A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow due to bone metastasis with DIC recovery by joint administration of 5-FU and paclitaxel]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2079-81
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow due to bone metastasis with DIC recovery by joint administration of 5-FU and paclitaxel].
  • Based on various tests, a diagnosis of scirrhous gastric carcinoma accompanied by bone metastasis and liver metastasis was made.
  • 5-FU+PTX therapy is considered to be effective for DIC due to bone metastasis of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / drug therapy. Bone Neoplasms / drug therapy. Disseminated Intravascular Coagulation / etiology. Liver Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197758.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


44. Akagi T, Etoh T, Eguchi H, Hiroishi K, Ueda Y, Yasuda K, Noguchi T, Shiraishi N, Kitano S: [A case of scirrhous gastric carcinoma with peritoneal dissemination which was treated by curative gastrectomy after S-1/CDDP chemotherapy]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1573-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of scirrhous gastric carcinoma with peritoneal dissemination which was treated by curative gastrectomy after S-1/CDDP chemotherapy].
  • Stable disease (SD) was obtained after six courses, and then she underwent second-staging laparoscopy.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716890.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 22
  •  go-up   go-down


45. Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, Kaizaki R, Miwa A, Hirakawa K: Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer; 2010 Feb 15;126(4):1004-16
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.
  • Scirrhous gastric carcinoma (SGC) carries the highest mortality because of a frequent metastasis to lymph node (LN).
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents / therapeutic use. Fluorouracil / therapeutic use. Indoles / therapeutic use. Pyrroles / therapeutic use. Receptor, Fibroblast Growth Factor, Type 2 / antagonists & inhibitors. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621385.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyridines; 0 / Pyrroles; 0 / RNA, Messenger; 0 / sunitinib; EC 2.7.10.1 / Fgfr2 protein, mouse; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2; U3P01618RT / Fluorouracil; UA8SE1325T / gimeracil
  •  go-up   go-down


46. Suzuki S, Ohchi T, Doi K, Ogata K, Maeda T, Kudo K, Ishihara A: [A case of advanced accessory breast cancer effectively treated with trastuzumab and paclitaxel]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1615-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological findings of axillary mass revealed infiltrating ductal carcinoma of scirrhous type.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / blood. Biopsy. Female. Humans. Immunotherapy. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799924.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


47. Huang KH, Chen JH, Wu CW, Lo SS, Hsieh MC, Li AF, Lui WY: Factors affecting recurrence in node-negative advanced gastric cancer. J Gastroenterol Hepatol; 2009 Sep;24(9):1522-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Prognostic factors of lymph node-negative gastric adenocarcinoma after curative resection have been discussed.
  • METHODS: Recurrent sites and correlated clinicopathological factors of 372 patients with lymph node-negative advanced gastric adenocarcinoma that underwent R0 resection from 1988 to 2005 were analyzed.
  • Clinicopathological factors to predict peritoneal seeding were serosal exposure, lymphovascular invasion, Lauren's diffuse type differentiation and scirrhous stromal reaction.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Gastrectomy. Hematologic Neoplasms / pathology. Neoplasm Recurrence, Local. Neoplasm Seeding. Stomach Neoplasms / secondary. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Kaplan-Meier Estimate. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Proportional Hazards Models. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol Hepatol. 2009 Sep;24(9):1478-9 [19743992.001]
  • (PMID = 19467143.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


48. Sato T, Nakagawa T, Kuwayama T, Kubota K, Suzuki S, Sugihara K: [A case of inflammatory breast cancer responding to anastrozole]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2477-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037461.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


49. Suzuki N, Katsusihma H, Takeuchi K, Nakamura S, Ishizawa K, Ishii S, Moriya T, DeCoteau JF, Miura I, Ichinohasama R: Cytogenetic abnormality 46,XX,add(21)(q11.2) in a patient with follicular dendritic cell sarcoma. Cancer Genet Cytogenet; 2008 Oct;186(1):54-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic abnormality 46,XX,add(21)(q11.2) in a patient with follicular dendritic cell sarcoma.
  • Although this patient suffered from breast carcinoma 6 years after the onset of FDC sarcoma, the carcinoma showed different histological and phenotypic profiles.
  • [MeSH-minor] Adenocarcinoma, Scirrhous / genetics. Axilla. Biomarkers, Tumor / analysis. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Fatal Outcome. Female. Humans. Immunophenotyping. Lymph Nodes / pathology. Middle Aged. Neoplasm Proteins / analysis. Receptors, Complement 3d / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786443.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Complement 3d
  •  go-up   go-down


50. Ishikawa T, Takashima T, Takagaki K, Ogawa Y, Onoda N, Nakata B, Kato Y, Hirakawa K: [A case of anthracycline and taxane-resistant breast cancer with life-thereatening multiple liver metastases responding to oral combination chemotherapy by UFT, cyclophosphamide and medroxyprogesterone acetate]. Gan To Kagaku Ryoho; 2005 May;32(5):687-90
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Administration, Oral. Anthracyclines / pharmacology. Bridged Compounds / pharmacology. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Drug Combinations. Drug Resistance, Neoplasm. Female. Humans. Medroxyprogesterone Acetate / administration & dosage. Middle Aged. Taxoids / pharmacology. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918574.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Bridged Compounds; 0 / Drug Combinations; 0 / Taxoids; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 1605-68-1 / taxane; 56HH86ZVCT / Uracil; 8N3DW7272P / Cyclophosphamide; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


51. Stern AW, Velguth KE, D'Agostino J: Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus). J Zoo Wildl Med; 2010 Jun;41(2):320-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus).
  • A 17-yr-old Western Hognose snake (Heterodon nasicus) presented with a prominent midcoelomic swelling.
  • Histologically, the mass was composed of tubules of columnar to flattened neoplastic cells with an abundant stroma and moderate cellular atypia consistent with a scirrhous adenocarcinoma, likely ductal in origin, given the location of the neoplastic mass.
  • Necropsy and histopathologic examination confirmed metastasis of the previously removed adenocarcinoma to the liver, right kidney, and large intestine.
  • [MeSH-major] Adenocarcinoma / veterinary. Snakes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597225.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Nomura M, Inoue Y, Fujita S, Sakao J, Hirota M, Souda S, Ohshima M: Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery. Breast Cancer; 2005;12(3):226-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological diagnosis was scirrhous carcinoma, g, ly1, v0, t2, n0, ER (-), PgR (+) and stage I A.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110294.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


53. Horii R, Akiyama F, Kasumi F, Koike M, Sakamoto G: Spontaneous " healing" of breast cancer. Breast Cancer; 2005;12(2):140-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focally localized healing often prevents confirmation of the continuity of intraductal carcinoma.
  • (1) The proportion of breast cancer with healing was 7% (21/311). (2) In the 21 patients, the mean age was 59.2 years, and the mean diameter was 2.8 cm. (3) The histological type of the breast cancer varied: noninvasive ductal carcinoma in 2 cases, papillotubular carcinoma in 5, solid-tubular carcinoma in 8, scirrhous carcinoma in 5, invasive lobular carcinoma in 1, and Paget's disease in 1.
  • However in all cases, the histologic type of the intraductal carcinoma foci was the comedo/solid type and the nuclear grade of cancer cells was high. (4) In cases with healing, areas of healing were seen in an average of 5 (1-26) blocks, compared with intraductal carcinoma foci in 13 blocks (2-40).
  • CONCLUSION: The proportion of breast cancer cases with healing was 7% and these cases were intraductal carcinoma of the comedo/solid type, consisting of highly malignant cancer cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / therapy. Carcinoma / therapy. Neoplasm Regression, Spontaneous / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Fibrosis. Humans. Mastectomy, Segmental. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858446.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


54. Okamura N, Yoshida M, Shibuya A, Sugiura H, Okayasu I, Ohbu M: Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int; 2005 Nov;55(11):724-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
  • Scirrhous hepatocellular carcinoma (SHCC) is a rare variation of HCC, for which characteristics of tumor cells and the fibrotic stroma have not been clarified in detail.
  • Diagnosis was on the basis of a scirrhous histological pattern exceeding 50% of the tumor area.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271085.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Collagen Type III; 0 / Laminin; 0 / Tenascin; 103107-01-3 / Fibroblast Growth Factor 2; 68238-35-7 / Keratins; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


55. Kuramitsu Y, Baron B, Yoshino S, Zhang X, Tanaka T, Yashiro M, Hirakawa K, Oka M, Nakamura K: Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells. Anticancer Res; 2010 Nov;30(11):4459-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells.
  • This study performed proteomic differential display analysis of human scirrhous-type gastric carcinoma (SGC) cell lines and normal gastric mucosa (NGM) tissues by using two-dimensional gel electrophoresis (2-DE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS).
  • Although OCUM-1 and AGS (gastric cancer) showed up-regulation of 14-3-3 sigma, MiaPaca-2 (pancreatic cancer), Huh-7 (HCC) and NCI-H2052 (malignant pleural mesothelioma) showed very weak expression of 14-3-3 sigma.
  • [MeSH-major] 14-3-3 Proteins / metabolism. Adenocarcinoma, Scirrhous / metabolism. Biomarkers, Tumor / metabolism. Exonucleases / metabolism. Gastric Mucosa / metabolism. Proteomics / methods. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115893.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


56. Yokoyama K, Tazawa Y, Suzuki I, Aoki Y, Shiramatsu K, Kobayashi J, Morishima Y, Kobayashi N, Toyoda Y, Fukada T, Horiguchi K, Yamamoto K, Nakano M, Miyazaki M: [A case of non-curatively resected scirrhous gastric cancer successfully treated over 2 years with weekly administration of paclitaxel]. Gan To Kagaku Ryoho; 2005 Mar;32(3):385-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-curatively resected scirrhous gastric cancer successfully treated over 2 years with weekly administration of paclitaxel].
  • The patient was a 66-year-old female with peritoneal metastasis and remarkable lymph node metastasis of scirrhous gastric cancer.
  • Weekly paclitaxel therapy is considered to be effective for the treatment of advanced scirrhous gastric cancer with peritoneal metastasis.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Gastrectomy. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791823.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


57. Yoshikawa T, Aoyama T, Watanabe T, Hayashi T, Ogata T, Cho H, Tsuburaya A, Kobayashi O: [Role of surgical resection for scirrhous gastric cancer with minimal peritoneal metastasis]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2264-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of surgical resection for scirrhous gastric cancer with minimal peritoneal metastasis].
  • Prognosis of scirrhous gastric cancer with minimal peritoneal metastasis was poor, and the role of resection has not been clarified yet.
  • [MeSH-major] Adenocarcinoma, Scirrhous / surgery. Peritoneal Neoplasms / secondary. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224542.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Akiyama F, Horii R: Therapeutic strategies for breast cancer based on histological type. Breast Cancer; 2009;16(3):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is generally accepted that the histological types of breast cancer are clinically significant because they serve as prognosticators and as the common language for improving the accuracy of clinical diagnosis.
  • It is necessary to diagnose breast cancer at the level of not only histological findings by needle biopsy, but also the histologic type based on diagnostic imaging and cytological diagnosis.
  • Preoperative drug therapy can be planned by making a histological diagnosis based on needle biopsy findings.
  • Preoperative drug therapy is not indicated for noninvasive carcinoma and papillotubular carcinoma (invasive carcinoma with predominant intraductal components).
  • While complete loss of interstitial infiltration can be expected with solid-tubular carcinoma, it cannot be expected with other histological types, such as invasive lobular carcinoma, adenoid cystic carcinoma, or metaplastic carcinoma (squamous-cell carcinoma and spindle-cell carcinoma).
  • On therapeutic response assessment, the clinical and pathological findings generally match for solid-tubular carcinoma but not for scirrhous carcinoma and invasive lobular carcinoma.
  • With mucinous carcinoma, mucus accumulation can remain, even though most cancer cells disappear; as a result, assessment based on tumor diameter changes is difficult.
  • Histological diagnosis is also significant from the viewpoint of drug sensitivity, and it is important to maintain the accuracy of histological diagnosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479319.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Yen YH, Wang JH, Lu SN, Chen TY, Changchien CS, Chen CH, Hung CH, Lee CM: Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia. Eur J Radiol; 2006 Dec;60(3):439-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We prospectively studied 37 hepatic tumors (34 patients), with a mean size of 2.9cm and each having a central feeding artery, by CDUS/PDUS.
  • The CEUS was performed with a galactose-based microbubble contrast agent.
  • RESULTS: CEUS showed a central feeding artery with a spoke-wheel sign in 36 tumors, including 34 FNHs and 2 hepatocellular carcinomas.
  • The two hepatocellular carcinomas showed scirrhous changes histologically.
  • Scirrhous hepatocellular carcinoma should be included in the differential diagnosis for liver tumors with spoke-wheel sign detected by CEUS.
  • [MeSH-minor] Adolescent. Adult. Biopsy. Carcinoma, Hepatocellular / ultrasonography. Contrast Media. Diagnosis, Differential. Female. Humans. Liver Neoplasms / ultrasonography. Magnetic Resonance Imaging. Male. Microbubbles. Middle Aged. Polysaccharides. Prospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916591.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  •  go-up   go-down


60. Iida S, Furukawa K, Yokoyama T, Yanagihara K, Iwasaki R, Noguchi T, Tsuchiya S, Sugisaki Y, Naito Z, Tajiri T: [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1697-700
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
  • We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide).
  • Pathological findings were as follows: invasive ductal carcinoma (scirrhous type), pT1c (2.0 cm), n (1/10), ly3, v1, ER (-), PgR (-), HER2: score 1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Capecitabine. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940394.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


61. Koizumi Y, Obata H, Hara A, Nishimura T, Sakamoto K, Fujiyama Y: A case of scirrhous gastric cancer with peritonitis carcinomatosa controlled by TS-1 + paclitaxel for 36 mo after diagnosis. World J Gastroenterol; 2007 Jan 21;13(3):470-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of scirrhous gastric cancer with peritonitis carcinomatosa controlled by TS-1 + paclitaxel for 36 mo after diagnosis.
  • A 34-year-old female complaining of abdominal fullness was diagnosed as scirrhous gastric cancer (type 4') with peritonitis carcinomatosa in July 2002.
  • The chemotherapy was effective for 28 mo, and then it was discontinued upon the patientos own request, and she survived for 36 mo after diagnosis.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Aug;12(8):1133-7 [11583196.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):84-9 [11823704.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):874-7 [12064011.001]
  • [Cites] Oncology. 2005;69(3):261-8 [16138002.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 6:S3-6 [7865431.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] ANZ J Surg. 2002 Oct;72(10):739-42 [12534387.001]
  • (PMID = 17230622.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC4065908
  •  go-up   go-down


62. Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I: Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol; 2006 Aug;30(8):945-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity.
  • The current histologic classifications of gastric cancers define only carcinoids and small cell carcinomas in the neuroendocrine (NE) category.
  • This study aimed to characterize the histologic and clinical features of high-grade gastric NE carcinomas of nonsmall cell type, tentatively named large cell neuroendocrine carcinoma (LCNEC).
  • Tumors with histologic features suspicious of NE differentiation were selected by a histologic review of 2835 resected gastric cancers, and those with a NE phenotype in > 50% and 1% to approximately 50% tumor cells assessed by expressing chromogranin A and/or synaptophysin were defined as LCNEC and adenocarcinoma with neuroendocrine differentiation (ACNED), respectively.
  • Generally, LCNECs demonstrated less predominant NE morphology than carcinoids, and could be roughly divided into solid (30 cases), tubular (7 cases), and scirrhous (5 cases) subtypes with reference to their main growth pattern.
  • The prognosis of LCNECs was significantly worse than that of conventional adenocarcinomas (P < 0.0001).
  • Furthermore, the prognosis of ACNEDs was also significantly worse than that of adenocarcinomas (P < 0.0001), and some ACNEDs might actually have been LCNECs, and survival analysis showed that > 20% positivity of NE markers could be enough to characterize LCNEC, as long as light microscopic NE morphology was present in the tumor.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Chromogranin A. Chromogranins / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Prognosis. Survival Analysis. Survival Rate. Synaptophysin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861964.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


63. Mimae T, Ninomiya M, Sasaki H, Kubo Y, Kojima T, Umeoka T, Takakura N: [A case of recurrent gastric cancer with improvement of obstructive symptoms caused by carcinomatous peritonitis and prolonged survival by chemotherapy with combined use of Paclitaxel and 5-FU]. Gan To Kagaku Ryoho; 2006 Feb;33(2):247-50
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 29-year-old male underwent Cur B surgery including total gastrectomy, pancreaticoduodenectomy, transverse colectomy, and D 2 dissection for scirrhous gastric carcinoma accompanied by duodenal and pancreatic infiltration.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ileus / etiology. Neoplasm Recurrence, Local / drug therapy. Peritonitis / therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484866.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


64. Nagata N, Nakayama Y, Matsumoto K, Inoue Y, Shibao K, Higure A, Hirata K, Itoh H: [A case of curatively resected schirrous gastric cancer effectively treated by combined chemotherapy of weekly paclitaxel (PTX) and CDDP]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2101-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352936.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


65. Terazaki Y, Nagamatsu H, Ono H, Iwakuma N, Shirouzu K: [A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia]. Gan To Kagaku Ryoho; 2005 May;32(5):675-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Alopecia / chemically induced. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Doxorubicin / analogs & derivatives

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918571.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


66. Ueno S, Nakakuma T, Aramaki N, Shiozawa K, Iizuka M, Kurita A, Miyauchi K, Sengoku N, Kuranami M: [A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2471-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel].
  • The patient was examined as scirrhous carcinoma by lacteal gland inspection and dysplastic cell by ascites cytotechnology.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Peritonitis / etiology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037459.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


67. Ohsako T, Inoue K, Nagamoto N, Yoshida Y, Nakahara O: [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment]. Gan To Kagaku Ryoho; 2006 Sep;33(9):1301-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological findings were as follows: invasive ductal carcinoma (scirrhous type), 2.2 cm in size, histological grade 3, positive invasion to the lymphatic and blood vessels, negative nodal status (0/11), negative ER/PgR status, and overexpression of HER 2/neu.
  • Pathological findings were as follows: invasive ductal carcinoma (scirrhous type), 1.8 cm in size, histological grade 2, positive invasion to the lymphatic and blood vessels, negative nodal status (0/5), positive ER and uncertain PgR status, and overexpression of HER 2/neu.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Lymph Nodes / pathology. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969029.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


68. Osako T, Ito Y, Morimatsu A, Tada K, Sakurai N, Takahashi S, Akiyama F, Iwase T, Hatake K: Flare-up of dermatomyositis along with recurrence of breast cancer. Breast J; 2007 Mar-Apr;13(2):200-2
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Dermatomyositis / etiology. Neoplasm Recurrence, Local / diagnosis. Paraneoplastic Syndromes / etiology
  • [MeSH-minor] Adenocarcinoma, Scirrhous / diagnosis. Adenocarcinoma, Scirrhous / therapy. Aged. Creatine Kinase / blood. Fatal Outcome. Female. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Mastectomy

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319865.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.3.2 / Creatine Kinase
  •  go-up   go-down


69. Chen CY, Jaw TS, Wu DC, Kuo YT, Lee CH, Huang WT, Liu GC: MDCT of giant gastric folds: differential diagnosis. AJR Am J Roentgenol; 2010 Nov;195(5):1124-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDCT of giant gastric folds: differential diagnosis.
  • OBJECTIVE: The purpose of this study was to evaluate the efficacy of MDCT in the differentiation of diseases involving giant gastric folds and to identify the features most useful for predicting the presence of malignant gastric disease.
  • Thirty of these patients had histopathologic results showing scirrhous carcinoma; 15, large B-cell lymphoma; 14, acute gastric mucosal lesions; and five, Ménétrier disease.
  • Unenhanced transparent volume-rendered images were assessed to determine the morphologic features of the whole stomach.
  • We used exact logistic regression to identify which MDCT image features were most predictive of the presence of malignant gastric disease.
  • CONCLUSION: MDCT may be a reliable means of noninvasive diagnosis in the care of patients with endoscopically detected giant gastric folds and may be useful for differentiating benign from malignant disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Gastroscopy. Humans. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies. Stomach Neoplasms / pathology. Stomach Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966317.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Tsuchiya S: Cytological characteristics of invasive lobular carcinoma of the human breast. Med Mol Morphol; 2008 Sep;41(3):121-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological characteristics of invasive lobular carcinoma of the human breast.
  • In contrast to invasive ductal carcinoma, invasive lobular carcinoma (ILC) of the breast is characterized by multiple ipsilateral occurrences and a higher incidence in the contralateral breast.
  • It is therefore necessary to examine thoroughly whether there is any other carcinoma present before any breast-conserving surgery is carried out.
  • We cytologically, histologically, and ultrastructurally investigated ILC and pure scirrhous carcinoma (PSC), a subtype of invasive ductal carcinoma, to establish cytological diagnostic criteria for the differential diagnosis of these two types of carcinoma that have high histological similarity.
  • The carcinoma showed a rosary-like configuration.
  • These findings may contribute to histological estimation of ILC in preoperative cytological diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Female. Humans. Mammary Glands, Human / cytology. Mammary Glands, Human / pathology. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807136.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


71. Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, Miyashiro I, Kaji M, Ninomiya M: Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer; 2009;12(1):37-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002).
  • BACKGROUND: The prognosis of scirrhous gastric cancer remains poor despite extended surgery or adjuvant or neoadjuvant chemotherapy.
  • Therefore, the Japan Clinical Oncology Group conducted a phase II trial to confirm the efficacy of S-1 for neoadjuvant chemotherapy against resectable scirrhous gastric cancer.
  • METHODS: Patients were eligible if they had typical scirrhous gastric cancer invading more than half of the stomach, and resectable disease confirmed by laparoscopic staging.
  • Toxicity was acceptable, with a few grade 3 (5.5%) events, but no grade 4 adverse events.
  • CONCLUSION: S-1 neoadjuvant chemotherapy appeared feasible and showed positive effects against scirrhous gastric cancer; however, the survival rate with S-1 did not reach the expected rate required when selecting an agent for a phase III trial to confirm the effectiveness of neoadjuvant chemotherapy against scirrhous gastric cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Combinations. Feasibility Studies. Humans. Japan. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19390930.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


72. Okita A, Miyade Y, Okano K: Effective management of an advanced gastric cancer patient by TS-1 combined chemotherapy using nasojejunal tube and successful transfer to home care after percutaneous transesophageal gastro-tubing (PTEG): a case report. Acta Med Okayama; 2010 Feb;64(1):67-70
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 67-year-old woman with debilitation and massive ascites was admitted to our hospital and diagnosed with stage IV scirrhous gastric cancer with peritoneal dissemination.
  • After 7 cycles, the disease progressed, and TS-1 combined with low-dose cisplatin was administered for 3 cycles.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Gastrostomy / methods. Intubation, Gastrointestinal / methods. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20200587.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


73. Tanigawa T, Miyamoto Y, Abe M, Hasuo T, Doiguchi M, Sakamoto F: [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1515-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
  • We experienced a case of inflammatory carcinoma, which has been well controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab.
  • A 54-year-old woman was diagnosed as inflammatory carcinoma with T4d, N3c, M0 in Stage III c.
  • The lesion was diagnosed as invasive ductal carcinoma, scirrhous, ER(-), PgR(-), HER2(3+) by core needle biopsy, The skin lesion was diagnosed as dermal lymphatic carcinomatosis by skin biopsy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma / drug therapy. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Inflammation. Middle Aged. Oxonic Acid / administration & dosage. Skin Neoplasms / drug therapy. Taxoids / administration & dosage. Tegafur / administration & dosage. Trastuzumab. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755823.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 5VT6420TIG / Oxonic Acid; 8N3DW7272P / Cyclophosphamide; P188ANX8CK / Trastuzumab; Q6C979R91Y / vinorelbine
  •  go-up   go-down


74. Tsubono M, Kaneko I, Kii E, Tanaka T, Murata T, Kamimura K, Deguchi Y, Nonogaki H, Yasumizu R: [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. Gan To Kagaku Ryoho; 2005 Mar;32(3):365-9
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Scirrhous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791819.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitriles; 0 / Triazoles; 039LU44I5M / Floxuridine; 2Z07MYW1AZ / anastrozole; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


75. Sasada S, Ninomiya M, Kobayashi J, Nishizaki M, Takakura N: [A case of long survival of a scirrhous gastric cancer patient with esophageal invasion and peritoneal dissemination through chemotherapy and palliative surgery]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1551-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long survival of a scirrhous gastric cancer patient with esophageal invasion and peritoneal dissemination through chemotherapy and palliative surgery].
  • We report a case of advanced scirrhous gastric cancer treated by operation and chemotherapy for over four years.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / secondary. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / blood. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Palliative Care. Treatment Failure

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799910.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


76. Ito Y, Arai K, Ryushi, Nozawa, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Kakudo K, Miyauchi A: S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma. Pathol Res Pract; 2005;201(8-9):551-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma.
  • S100A9, a calcium-binding protein, is associated with myeloid cell differentiation and is expressed in some adenocarcinomas as well as in squamous epithelia and squamous cell carcinoma.
  • S100A9 was absent in normal follicles, follicular adenoma, and follicular and papillary carcinomas with conventional growth structures.
  • In lesions showing a solid, trabecular, or scirrhous growth pattern, S100A9 immunoreacitivity was occasionally observed.
  • One (5.9%) of the 17 follicular carcinomas and three (7.8%) of the 38 papillary carcinomas were regarded as positive for S100A9, but the positive cell areas always accounted for 5% or less.
  • However, S100A9 was positive in all 19 undifferentiated carcinomas examined.
  • It is therefore suggested that S100A4 protein plays an important role in thyroid carcinoma dedifferentiation, and can be considered a novel characteristic of undifferentiated carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Calgranulin B / metabolism. Carcinoma, Papillary / metabolism. Cell Transformation, Neoplastic / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259107.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calgranulin B
  •  go-up   go-down


77. Takeda Y, Yoshikawa K: Contrast-enhanced dynamic MR imaging parameters and histological types of invasive ductal carcinoma of breast. Biomed Pharmacother; 2005 Apr;59(3):115-21
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced dynamic MR imaging parameters and histological types of invasive ductal carcinoma of breast.
  • The diagnosis of breast cancer has progressed owing to the improvement of both MRI equipments and MR techniques.
  • CE-MRI is expected to be more useful for diagnosis of the existence and characteristics of breast cancer than mammography and ultrasound.
  • Forty-three breast cancer patients, who underwent breast MRI examination before surgery and had histologically confirmed invasive ductal carcinomas, were included in this study.
  • In 19, seven and 17 of them, carcinomas were histologically classified as papillotubular, solid-tubular, and scirrhous type, respectively.
  • Four of 15 parameters analyzed, ENH1-2, ENH1, MSLP, and SAT3, were significantly different between papillotubular and scirrhous carcinoma.
  • The dynamic curve of papillotubular carcinoma reached a maximum in the very early phase and then decreased slowly (linear pattern), while that of scirrhous carcinoma peaked in the slightly later phase and then decreased (parabolic pattern).
  • In the differential analysis by Kruskal-Wallis test, although no significant differences were found in any morphological parameters among three histological types, spicula formation and rim enhancement tended to appear comparatively frequently in scirrhous and solid-tubular carcinoma.
  • CE-MRI might reveal the differences of growth characteristics among different histological types of breast carcinomas and provide a diagnostic method useful for estimation of the prognosis of breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15795104.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] France
  •  go-up   go-down


78. Yoshida K, Yamaguchi S, Kawaguchi A: [A case of scirrhous gastric cancer with peritoneal metastases successfully treated by combined chemotherapy of biweekly paclitaxel and TS-1 followed by curative resection]. Gan To Kagaku Ryoho; 2007 Apr;34(4):601-4
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of scirrhous gastric cancer with peritoneal metastases successfully treated by combined chemotherapy of biweekly paclitaxel and TS-1 followed by curative resection].
  • We thought a complete resection would be difficult, so he was given neoadjuvant chemotherapy combined with paclitaxel (200 mg, day 1, 15) and TS-1 (120 mg/day, for days 1-14 with a 2-week rest).
  • The pathological diagnosis was sig, LM, type 4, pT 3 (SE), sci, INFgamma, ly 0, v 0, pN 0, pPM (-), pDM (-), and the antitumor efficacy of this therapy was Grade 0 histologically.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431348.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


79. Yagi Y, Fushida S, Harada S, Kinoshita J, Makino I, Oyama K, Tajima H, Fujita H, Takamura H, Ninomiya I, Fujimura T, Ohta T, Yashiro M, Hirakawa K: Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res; 2010;29:149
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line.
  • This study was performed to investigate the inhibitory effects of valproic acid (VPA) on a highly peritoneal-seeding cell line of human scirrhous gastric cancer, OCUM-2MD3, and to explore the mechanism and the potential of VPA.
  • Therefore, VPA in combination with PTX is expected to be a promising therapy for peritoneal dissemination of scirrhous gastric cancer.
  • [MeSH-minor] Acetylation. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Animals. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Female. Histone Deacetylase 1 / metabolism. Histone Deacetylase 2 / metabolism. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Mice, Nude. Neoplasm Invasiveness. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):169-90 [20467795.001]
  • [Cites] Br J Cancer. 2010 Mar 2;102(5):844-51 [20145621.001]
  • [Cites] Mol Cancer Ther. 2002 Sep;1(11):937-41 [12481415.001]
  • [Cites] EMBO J. 2003 Mar 3;22(5):1168-79 [12606581.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):665-8 [12642691.001]
  • [Cites] EMBO J. 2003 Jul 1;22(13):3411-20 [12840003.001]
  • [Cites] Int J Cancer. 2004 Mar 20;109(2):182-8 [14750167.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1079-86 [14871841.001]
  • [Cites] Lancet. 1994 Nov 5;344(8932):1267-72 [7967989.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1668-75 [8608560.001]
  • [Cites] Jpn J Cancer Res. 1997 Feb;88(2):152-9 [9119743.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):582-7 [9778627.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:295-312 [10331086.001]
  • [Cites] Eur J Med Chem. 2005 Jan;40(1):1-13 [15642405.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):11-8 [15688418.001]
  • [Cites] APMIS. 2005 Apr;113(4):264-8 [15865607.001]
  • [Cites] Oncol Rep. 2005 Jun;13(6):1139-44 [15870934.001]
  • [Cites] CA Cancer J Clin. 2005 Nov-Dec;55(6):334-51 [16282279.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):355-62 [10639581.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):992-7 [11093826.001]
  • [Cites] Exp Cell Res. 2001 Jan 15;262(2):75-83 [11139331.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2000;10(3-4):303-25 [11272471.001]
  • [Cites] J Pain Symptom Manage. 2001 Mar;21(3):204-9 [11239739.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):6969-78 [11742974.001]
  • [Cites] Jpn J Cancer Res. 2001 Dec;92(12):1300-4 [11749695.001]
  • [Cites] Chem Biol. 2002 Jan;9(1):3-16 [11841934.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):504-13 [11929951.001]
  • [Cites] Nature. 2002 May 23;417(6887):455-8 [12024216.001]
  • [Cites] World J Gastroenterol. 2002 Jun;8(3):400-5 [12046058.001]
  • [Cites] PLoS Med. 2005 Dec;2(12):e354 [16250671.001]
  • [Cites] Curr Opin Pharmacol. 2006 Aug;6(4):369-75 [16781195.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):563-8 [16865256.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2203-10 [16985053.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2767-76 [17121923.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):510-7 [17164226.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):177-82 [17579623.001]
  • [Cites] J Surg Res. 2007 Aug;141(2):183-91 [17574589.001]
  • [Cites] Oncol Rep. 2007 Oct;18(4):769-74 [17786334.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):839-45 [17914112.001]
  • [Cites] Biochim Biophys Acta. 2007 Oct;1773(10):1572-82 [17610967.001]
  • [Cites] Curr Med Chem. 2007;14(24):2548-53 [17979707.001]
  • [Cites] Biochem J. 2008 Jan 15;409(2):581-9 [17868033.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):139-48 [18207460.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1305-10 [18425392.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Jun;8(4):266-74 [18537550.001]
  • [Cites] J Biochem. 2008 Sep;144(3):357-62 [18515856.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6296-301 [18829512.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):28-36 [19127265.001]
  • [Cites] Surg Today. 2009;39(4):290-4 [19319634.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2488-96 [19318486.001]
  • [Cites] Postepy Biochem. 2009;55(2):121-8 [19824467.001]
  • [Cites] Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23 [19838011.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L864-70 [19700647.001]
  • [Cites] Ann Oncol. 2010 Jan;21(1):67-70 [19605503.001]
  • [Cites] Lab Invest. 2010 Mar;90(3):436-47 [20142807.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):874-7 [12064011.001]
  • (PMID = 21080974.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histones; 0 / Tubulin; 614OI1Z5WI / Valproic Acid; EC 3.5.1.98 / HDAC1 protein, human; EC 3.5.1.98 / HDAC2 protein, human; EC 3.5.1.98 / Histone Deacetylase 1; EC 3.5.1.98 / Histone Deacetylase 2
  • [Other-IDs] NLM/ PMC2994814
  •  go-up   go-down


80. Hirono Y, Katayama K, Murakami M, Iida A, Yamaguchi A: [Intraperitoneal chemotherapy in gastric cancer patients with peritoneal dissemination]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1404-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CHPP has a marked survival benefit for scirrhous type gastric cancer patients without liver metastasis.
  • [MeSH-minor] Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / secondary. Adenocarcinoma, Scirrhous / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Gastrectomy. Humans. Infusions, Parenteral. Mitomycins / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227738.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Mitomycins; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


81. Fukuda Y, Fujio N, Ihara T, Takatori H, Tsukazaki T, Koyama I, Tsukazaki Y, Osugi H: [A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1945-8
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 50-year-old man was diagnosed with non-resectable scirrhous gastric cancer of antrum accompanied with colon ileus due to direct invasion of the transverse colon.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colon, Transverse / pathology. Colonic Neoplasms / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Floxuridine / administration & dosage. Humans. Ileus / etiology. Male. Middle Aged. Neoplasm Invasiveness. Paclitaxel / administration & dosage. Peritoneal Neoplasms / secondary. Quality of Life

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


82. Snyder MJ, Bentley R, Robboy SJ: Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int J Gynecol Pathol; 2006 Apr;25(2):155-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis.
  • Most endometrial carcinomas metastasize by invading myometrial lymphatics and spreading to regional lymph nodes.
  • However, uterine serous carcinomas (USCs) metastasize frequently to peritoneal surfaces even when only minimally invasive.
  • This explains the phenomenon whereby patients with serous carcinomas confined to the endometrium and lacking LV invasion have widespread metastases to the peritoneum.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Adenocarcinoma, Scirrhous / secondary. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / secondary. Neoplasm Metastasis
  • [MeSH-minor] Fallopian Tubes / pathology. Female. Humans. Hysterectomy. Neoplasm Invasiveness. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Peritoneum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633065.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Sasaki T, Koizumi W, Higuchi K, Ishido K, Ae T, Nakatani K, Katada C, Tanabe S, Saigenji K: [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint]. Gan To Kagaku Ryoho; 2007 Jul;34(7):988-92
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S-1 showed a higher response rate for undifferentiated-type adenocarcinoma, and S-1 alone or its combination regimens demonstrated greater anti-tumor effects and longer survival time for gastric linitis plastica compared with conventional 5-FU regimens in our historical control study (response rate: S-1/non S-1 57.9%/27.9%, p<0.01; MST: S-1/non S-1 402 days/213 days, p<0.01).
  • Paclitaxel also has a high response rate for undifferentiated-type adenocarcinoma, and can be expected to show high efficacy for peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637532.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


84. Okada K, Kijima H, Imaizumi T, Hirabayashi K, Matsuyama M, Yazawa N, Oida Y, Dowaki S, Tobita K, Ohtani Y, Tanaka M, Inokuchi S, Makuuchi H: Wall-invasion pattern correlates with survival of patients with gallbladder adenocarcinoma. Anticancer Res; 2009 Feb;29(2):685-91
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wall-invasion pattern correlates with survival of patients with gallbladder adenocarcinoma.
  • Gallbladder carcinomas (GBC) frequently show vascular invasion and metastasis when the carcinoma cells invade the perimuscular connective tissue (pT2 according to the TNM classification) through the muscular layer.
  • Sixty-six surgically resected gallbladder adenocarcinomas invading the perimuscular connective tissue (pT2) and beyond the gallbladder wall, including the visceral serosa, (pT3/pT4) were examined.
  • Lymphatic invasion (37.5% of IG and 62.5% of DG, p = 0.014), venous invasion (41.9%, 58.1%, p = 0.089), nodal status (30.4%, 69.6%, p = 0.015) and scirrhous growth (INFgamma) (31.0%, 69.0%, p = 0.0035) were more frequently detected in DG cases than in IG cases.
  • The patients with a high grade of lymphatic and venous invasion had lower survival rates (p < 0.0001 and p < 0.05, respectively).
  • The patients with the DG type and scirrhous growth (INFgamma) also had lower survival rates (p < 0.05 and p < 0.0001, respectively) than did patients with the IG type and expansive/intermediate growth (INFalpha,beta).
  • In conclusion, the DG invasion pattern is an indicator of high malignant potential and indirectly worsens the prognosis of patients with gallbladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331223.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


85. Matsumoto K, Yoshinouchi S, Takano Y, Kanzaki M, Maeda M, Miyoshi S, Wakita T, Teshima S: [Efficacy of FEC and trastuzumab/docetaxel combination therapy for metastatic breast cancer]. Gan To Kagaku Ryoho; 2010 Mar;37(3):503-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Core needle biopsy demonstrated scirrhous carcinoma.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Neoplasm Metastasis. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332692.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  •  go-up   go-down


86. Chen LL, Nolan ME, Silverstein MJ, Mihm MC Jr, Sober AJ, Tanabe KK, Smith BL, Younger J, Michaelson JS: The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. Cancer; 2009 Nov 1;115(21):5071-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: : Nine prognostic factors were identified that made marked, independent contributions to breast carcinoma lethality: grade; mucinous, medullary, tubular, and scirrhous adenocarcinoma; male sex; inflammatory disease; Paget disease; and lymph node status.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19658184.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Kishimoto T, Imamura H, Kawabata R, Fukunaga M, Ohzato H, Furukawa H: [Three scirrhous gastric cancer cases with CY negativity in second-look staging laparoscopy after chemotherapy to whom curative surgery was carried out]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2306-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three scirrhous gastric cancer cases with CY negativity in second-look staging laparoscopy after chemotherapy to whom curative surgery was carried out].
  • Case 1: A 77-year-old female with scirrhous gastric cancer was diagnosed as c4T3N1H0M0P0CY1/stage IV, and S-1/docetaxel combined therapy was carried out.
  • Case 2: A 48-year-old female with scirrhous gastric cancer was diagnosed as c4T3N1H0M0P0CY1/stage IV, and S-1/CDDP/paclitaxel combined therapy was carried out.
  • Case 3: A 37-year-old man with scirrhous gastric cancer was diagnosed as c4T3N0H0M0P1CY1/stage IV, and S-1/CDDP/paclitaxel combined therapy was carried out.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Adenocarcinoma, Scirrhous / therapy. Laparoscopy. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037404.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


88. Perez-Pinera P, Chang Y, Deuel TF: Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle; 2007 Dec 1;6(23):2877-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importantly, properties of different cells induced by PTN in PTN-stimulated cells are strikingly similar to properties of highly malignant cells.
  • Furthermore, transformed cells into which Ptn is introduced undergo "switches" to malignant cells of higher malignancy with properties that are strikingly similar to properties of PTN-stimulated cells.
  • These unique features of PTN support the conclusion that constitutive PTN signaling in malignant cells that inappropriately express Ptn functions as a potent tumor promoter.
  • Recently, in confirmation, Ptn targeted by the mouse mammary tumor virus (MMTV) promoter in a transgenic mouse model was found to promote breast cancers to a more aggressive breast cancer cell phenotype that morphologically closely resembles scirrhous carcinoma in human; in addition, it promoted a striking increase in tumor angiogenesis and a remarkable degree of remodeling of the micro-environment.
  • Pleiotrophin thus regulates both different normal and pathological functions; collectively, the different studies have uncovered the unique ability of a single cytokine PTN, which signals through the unique PTN/RPTPbeta/zeta signaling pathway, to induce the many properties associated with tumor promotion in the malignant cells that constitutively express Ptn and in their microenvironment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156802.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 2 T32 DK007022-26; United States / NCI NIH HHS / CA / CA84400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cytokines; 0 / Growth Substances; 134034-50-7 / pleiotrophin
  • [Number-of-references] 80
  •  go-up   go-down


89. Nakamura Y, Aono T, Nomura M, Iwase K, Tanaka Y: [Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine]. Gan To Kagaku Ryoho; 2010 Nov;37(11):2165-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first patient was a 59-year-old woman who was diagnosed with invasive scirrhous carcinoma.
  • The second patient was a 74-year-old woman who was diagnosed with invasive ductal carcinoma in 2005.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Receptor, ErbB-2 / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084819.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Quinazolines; 0VUA21238F / lapatinib; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; U3P01618RT / Fluorouracil
  •  go-up   go-down


90. Erkan M, Reiser-Erkan C, Michalski CW, Deucker S, Sauliunaite D, Streit S, Esposito I, Friess H, Kleeff J: Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia; 2009 May;11(5):497-508
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma.
  • BACKGROUND AND AIMS: Although both cancer and stellate cells (PSCs) secrete proangiogenic factors, pancreatic cancer is a scirrhous and hypoxic tumor.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Cell Communication / physiology. Extracellular Matrix / metabolism. Neovascularization, Pathologic / metabolism. Pancreatic Neoplasms / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Actins. Antigens, CD31 / biosynthesis. Cell Adhesion Molecules / biosynthesis. Cell Hypoxia / physiology. Enzyme-Linked Immunosorbent Assay. Fibrosis / metabolism. Humans. Immunoblotting. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4264-6 [8797602.001]
  • [Cites] Gut. 1999 Apr;44(4):534-41 [10075961.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1041-56 [10353737.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):89-93 [15545970.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):907-21 [15825074.001]
  • [Cites] Histopathology. 2005 Jun;46(6):668-76 [15910598.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4421-32 [15856026.001]
  • [Cites] Mol Biol Cell. 2005 Aug;16(8):3488-500 [15901832.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):512-9 [17227797.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):218-27 [17224648.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):1942-53 [17525262.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5076-82 [17545583.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):137 [17585412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12890-5 [17652168.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):918-26 [18245495.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2085-93 [18381413.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G709-17 [18669622.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Oct;6(10):1155-61 [18639493.001]
  • [Cites] Cancer Biol Ther. 2008 Sep;7(9):1352-9 [18708761.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):247-51 [11119712.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):519-27 [11923608.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Am Rev Respir Dis. 1989 Oct;140(4):1104-7 [2478057.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6180-4 [1718597.001]
  • [Cites] Cell. 1998 Sep 18;94(6):715-25 [9753319.001]
  • (PMID = 19412434.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD31; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human
  • [Other-IDs] NLM/ PMC2671860
  •  go-up   go-down


91. Toyokawa T, Sawada T, Muguruma K, Kim T, Kimura K, Inoue T, Yamashita Y, Yashiro M, Ohira M, Hirakawa K: [A case of advanced gastric cancer with malignant ascites responding to weekly paclitaxel therapy]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1637-40
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with malignant ascites responding to weekly paclitaxel therapy].
  • A 54-year-old woman with scirrhous gastric cancer in the upper third area was admitted to our hospital.
  • After 2 courses, malignant ascites completely disappeared and bilateral hydronephrosis improved.
  • Weekly paclitaxel therapy is suggested to be one of the safe and useful treatments for advanced gastric cancer with malignant ascites.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Ascites / drug therapy. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108715.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


92. Tanabe D, Kondou K, Uchiyama T, Noda K: [A case of scirrhous gastric cancer with peritoneal dissemination acquiring stable disease over three years by treatment with oral anticancer drug S-1]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1391-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of scirrhous gastric cancer with peritoneal dissemination acquiring stable disease over three years by treatment with oral anticancer drug S-1].
  • A 71-year-old male, who complicated of abdominal distension, was diagnosed as scirrhous gastric cancer.
  • We treated him with the oral anticancer drug S-1 and achieved long-term stable disease over three years.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oxonic Acid / administration & dosage. Oxonic Acid / therapeutic use. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701856.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


93. Akda F, Hafezi F, Heule-Dieleman HA, van den Bosch WA, Luyten GP, Tanghe HL, Paridaens D: [Orbital metastases of breast cancer. Radiologic features]. Ophthalmologe; 2010 Aug;107(8):728-32
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen consecutive patients with orbital metastases originating from breast carcinoma were identified between March 1997 and September 2008.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Orbital Neoplasms / diagnosis. Orbital Neoplasms / secondary. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma, Scirrhous / diagnosis. Adenocarcinoma, Scirrhous / pathology. Adenocarcinoma, Scirrhous / radiography. Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Eye Diseases / diagnosis. Eye Diseases / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Orbit / pathology. Retrospective Studies. Vision Disorders / diagnosis. Vision Disorders / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393728.001).
  • [ISSN] 1433-0423
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Sugitani I, Toda K, Yamamoto N, Sakamoto A, Fujimoto Y: Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country. World J Surg; 2010 Jun;34(6):1265-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country.
  • BACKGROUND: Poorly differentiated thyroid carcinoma (PDTC) was recognized as an independent clinicohistological entity of thyroid cancer in the 2004 World Health Organization (WHO) classifications, separated from papillary (PTC) and follicular carcinoma (FTC).
  • The Turin proposal provides more specific criteria for the diagnosis of PDTC.
  • In 1983, Sakamoto analyzed pathological characteristics of PTC and FTC that recurred within 5 years after initial surgery and identified solid, trabecular, insular (STI) and scirrhous growth patterns as important predictors of poor prognosis.
  • Disease-free survival was identical between these groups and was significantly worse than in the >0% but <10% and 0% groups.
  • According to multivariate analysis, histological features of STI >or=10% and squamous metaplasia were significantly related to cause-specific survival, but scirrhous infiltration, necrosis, nuclear atypia, and vascular invasion were not.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Disease-Free Survival. Female. Humans. Iodine. Japan / epidemiology. Male. Middle Aged. Prognosis. Proportional Hazards Models. Risk Factors. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953247.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9679TC07X4 / Iodine
  •  go-up   go-down


95. Nakamura M, Kubo N, Morimoto J, Tanaka H, Muguruma K, Amano R, Noda E, Inoue T, Takashima T, Yamada N, Yashiro M, Yamashita Y, Maeda K, Onoda N, Sawada T, Nakata B, Ohira M, Ishikawa T, Hirakawa K: [A case of type 4 gastric cancer with positive peritoneal lavage cytology, which relapsed at the peritoneum at the time of seven years and eight months after resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2436-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 55-year-old woman was admitted to our hospital with a complaint of appetite loss and body weight loss.
  • A clinical finding was Stage IIIB (T3N2M0) Type 4 gastric cancer of poorly differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Drug Combinations. Female. Gastrectomy. Humans. Lymph Node Excision. Middle Aged. Neoplasm Recurrence, Local. Oxonic Acid / therapeutic use. Peritoneal Lavage. Splenectomy. Tegafur / therapeutic use. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224598.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


96. Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y, Adjuvant CEF Research Group for Breast Cancer: Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer; 2010 Jul;17(3):190-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The overall 5-year survival was 77.1% for CEF and 71.4% for CMF [p = 0.24; hazard ratio 0.79 (95% CI 0.50-1.24)], and the 5-year disease-free survival was 55.7% for CEF and 48.9% for CMF [p = 0.15; hazard ratio 0.80 (95% CI 0.57-1.12)].
  • Although the log-rank test did not show a significant difference, both overall and disease-free survivals were higher for CEF according to the point estimates.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Papillary / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575284.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


97. Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Ota F, Nakamura R, Shimizu Y, Kawago M, Hirai Y, Naito K, Kiyoi M, Tanino H, Okamura Y, Furukawa T: In vitro evaluation of dose-response curve for paclitaxel in breast cancer. Breast Cancer; 2007;14(4):401-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / secondary. Adenocarcinoma, Scirrhous / surgery. Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Evaluation Studies as Topic. Female. Humans. Middle Aged. Neoplasm Invasiveness. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986806.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


98. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M: The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer; 2007;14(3):260-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Positron emission tomography (PET) is a non-invasive imaging modality used in the diagnosis and staging of breast cancer.
  • MATERIAL AND METHODS: PET studies were performed preoperatively on 37 patients with breast carcinoma.
  • [MeSH-minor] Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adenocarcinoma, Scirrhous / radionuclide imaging. Adult. Aged. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radionuclide imaging. Female. Humans. Injections, Intravenous. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Hormone-Dependent / metabolism. Neoplasms, Hormone-Dependent / pathology. Neoplasms, Hormone-Dependent / radionuclide imaging. Positron-Emission Tomography. Receptor, ErbB-2. Receptors, Estrogen. Receptors, Progesterone

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690502.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


99. Konishi K, Hasegawa N, Kaneko H, Iimura Y, Shoji Y, Kawabata M: [A case of stage IV breast cancer with large cancer ulcer responding to combination therapy of capecitabine and medroxyprogesterone acetate and cyclophosphamide]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1525-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After pathological examination from the ulcer, she was diagnosed as breast cancer, scirrhous carcinoma.
  • The efficacy was judged as stable disease (SD).
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755825.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 8N3DW7272P / Cyclophosphamide; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 2.7.10.1 / Receptor, ErbB-2; U3P01618RT / Fluorouracil
  •  go-up   go-down


100. Kusama R, Takayama F, Tsuchiya S: MRI of the breast: comparison of MRI signals and histological characteristics of the same slices. Med Mol Morphol; 2005 Dec;38(4):204-15
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of MRI with high spatial resolution and a special breast coil has contributed to more-accurate diagnosis of breast tumor, such as determination of morphologic characteristics including internal architecture of the breast lesion.
  • However, a subtype of fibroadenoma, mastopathic type, with a poorly defined border on CFT1 and carcinoma-like enhancement, is similar to cancer on MRI.
  • Scirrhous carcinomas take either of two patterns on dynamic MRI, i.e., homogeneous enhancement or thick irregular peripheral ring enhancement.
  • The latter type shows central fibrosis zones histologically.
  • Papillotubular carcinoma shows a spotted pattern on dynamic MRI.
  • Solid-tubular carcinoma shows thin peripheral enhancement on dynamic MRI and linear high signal on CFT1.
  • This finding of CFT1 corresponds to infiltration of lymph cells and fibroblast cells in the adjacent zone.
  • Invasive lobular carcinoma shows nonmass lesions and a slow gradual enhancement pattern.
  • Mucinous carcinomas show high signal intensity on T2-weighted images because of mucin and reveal gradual enhancement.
  • The ill-defined border of mucinous carcinoma on CFT1 is useful to distinguish it from FA.
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16378229.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down






Advertisement